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ABSTRACT
This thesis consists of two groups of prospective short-term
studies; the first group evaluates the technique of
knemometry and lower leg length(LLL) changes in a group of
healthy children and adults; the second group of studies is
based on short-term anthropometric changes in children on
treatment for acute lymphoblastic leukaemia(ALL).
Studies in the healthy group were performed on 26 prepubertal
children and 9 young adults. The first study refined the
technique of knemometry by minimizing intra-observer bias;
despite reducing bias knemometry remained a highly precise
form of measuring changes in LLL. The next study in this
group of subjects showed the presence of significant
intradaily variation in the LLL of some fully grown adults
and the influence of change in body weight and oedema on LLL.
There was no distinct pattern of lower leg changes in these
children when followed up for a period of 12 weeks by weekly
measurements or when followed up daily for a period of 4
weeks. The growth pattern was non-linear in nature and the
daily changes were not statistically related to nocturnal
urinary growth hormone (uGH) excretion, a non-invasive marker
of growth hormone secretion.
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Studies of short-term growth in ALL were performed on 25
children 14 of whom had knemometry during the two year
protocol for a median duration of 56 weeks. Conventional
anthropometric studies as well as knemometry showed an
adverse effect of intensive chemotherapy(CT) on growth. The
effects on growth seemed to be transient with evidence of
catch-up growth during less intensive periods of CT. Lower
leg growth during continuation CT was comparable to that seen
in healthy children and fluctuations in growth were
associated with changes in neutrophil counts. The sitting
height:height ratio reduced temporarily over the period of
remission induction and although the initial deceleration in
LLL improved immediately after induction, total axial growth
took longer to improve suggesting a transient but
disproportionately greater adverse effect of CT on the
vertebral spine.
A study of biochemical markers of bone and collagen turnover
in 16 subjects over the first six months of CT showed changes
consistent with catch-up growth and similar to that found by
knemometry. An uncoupling of bone turnover favouring bone
degradation during the intensive phases of CT and favouring
bone formation during the phase of catch-up growth was also
evident.
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Studies of uGh, insulin-like growth factor-I(IGF-I) and IGF
Binding Protein-3(IGFBP-3) in the 8 subjects who had
knemometry showed a possibility of a state of partial growth
hormone resistance at presentation and during the first few
weeks of CT where IGF-I and IGFBP-3 levels were not raised
despite high uGH excretion. Catch-up growth, observed as a
supraphysiologically high LLL velocity, occurred in the
presence of high uGH levels and normal IGF-I and IGFBP-3
levels suggesting that catch-up growth might be partly
independent of GH/IGF-I action.
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AIMS OF THE THESIS
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The present studies were designed to investigate the
short-term effects of chemotherapy on growth and bone
metabolism in order to provide insights into the mechanism
of any long-term changes. By employing recently developed
indicators of growth hormone secretion and bone & collagen
turnover, the study also evaluated the use of these
markers in assessing the effects of chemotherapy on
growth.
The aims of these studies were to:-
1. Evaluate the significance of short-term lower leg
length fluctuations in healthy individuals.
2. Document the pattern of growth using knemometry and
anthropometry in a group of children on treatment for
ALL .
3. Evaluate the effects of chemotherapy on markers of GH
secretion and bone & collagen turnover.
4. Investigate any relationships between the short-term






Section 1. The assessment of short-term growth
Longitudinal growth studies allow assessment of individual
growth patterns and differences in tempo of growth between
individuals. The commonest method of accurately assessing
growth in children has been by measuring total body stature
with the stadiometer (Cameron, 1986). Because of the
technical variability these measurements cannot reliably
detect changes in growth velocities from less than six-month
periods (Marshall, 1971); this is specially important when
growth is assessed in populations where the growth rate might
be particularly low such as prepubertal children as well as
those suffering from growth-suppressing illness.
A . The Knemometer
Over the last two decades the knemometer (knemo: Greek for
lower leg) has been developed to study the process of human
growth in much finer detail (Valk, 1983). This instrument
measures from the bottom of the heel to the top of the knee
when the subject is sitting in a carefully controlled
position with the knee flexed to an angle of just less than
90° (Fig.2.1). The instrument occupies an area of about 1.5m2
and is 1.7m high, consists of a seat (A) that can be moved in
horizontal and vertical planes so that the exact position of
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the subject may be recorded and reproduced on subsequent
occasions. In addition to the seating position the placement
of the foot on the base is also standardised with a
template(B) produced at the first measurement. The latter is
made by lowering a plate(C) attached to a digital ruler(D)
onto the knee. The vertical length is displayed on a digital
meter(E) and the maximum length is obtained by moving the LL
forward and backward and then medially and laterally until
the digital meter displays the maximum value. Other controls
present on the digiruler include a "reset" button which is
used for zeroing the device and a "preset" button which is
for calibrating the digiruler. Each measurement is derived
from a set of 4 "estimations"; the most deviant of the 4
estimations is eliminated and the mean of the rest is
calculated to provide a "measurement" (Wales & Milner, 1987) .
In between each estimation the subject walks a standard
distance, such as around the knemometer, so that the
conditions for each estimation are standardised.
Recently, portable hand-held knemometers have been devised
and these are easier to use in younger children and infants
who are too young to sit still for long enough (Bisgaard,
1993, Gibson et al, 1993) .A portable knemometer for older
subjects has also been recently described (Davies et al,
1996).
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The knemometer can measure the LL non-invasively with an
accuracy of 0.1mm and a reported technical error (TE,one
standard deviation from the mean of repeated estimates) of
0.09mm-0.16mm (Hermanussen, 1988). It should be noted,
however, that the operator is aware of the preceding
estimates in the series and the measurement process is
therefore subject to intra-observer bias as the operator
inadvertently tries to equal the previous estimates and as a
consequence reduces the technical error resulting in a
measurement which might be artificially precise.
Besides studying the pattern of normal growth, the knemometer
has also been used to predict the effect of growth promoting
therapies such as Growth Hormone(GH) treatment (Wales &
Milner, 1989), documenting the effect of corticosteroids in
disease states such as asthma (Wolthers & Pedersen, 1992) and
inflammatory bowel disease (Wales & Milner, 1989) and
studying the effect of dialysis in children with chronic
renal failure (Seidel et al, 1991).
B . Intradaily Variation of Lower Leg Length
Postural changes in height through the day have been
quantified since the 18th century; Wasse demonstrated that
height loss through the day in adults could be as much as
(6/10s of an inch', occured more in young adults and was due
to changes in the back and not the legs (Wasse, 1724) . The
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knemometer has shown similar reductions in LL length (LLL) of
children but no such studies have been performed in adults
(Valk, 1983) . The reduction is thought to be due to
gravitational effects on the compressible components of the
LL such as the soft tissue and the epiphyses. Physical
activity prior to the knemometric measurement leads to a
significant decrease in LLL in children and an increase in
adults (Hermanussen et al, 1988(a)); this temporary effect
tends to disappear 2 hours following activity.
C . Saltatory Growth
Variation in height velocity in relation to season (Butler et
al, 1990) as well as so-called mid-childhood growth
spurts(Berkey et al, 1983) have been well documented. Recent
studies of infants looking at short-term changes in total
recumbent length and head circumference have shown a
saltatory process of 'incremental bursts' of growth on
background stasis (Lampl et al, 1992). Moreover different
parts of the body grow at different rates as suggested by
differential longitudinal growth rate of the spine and sub-
ischial leg (Ashizawa & Kawabata, 1990) .
Knemometry has shown that LL growth in healthy children is
also seasonally variable (Gelander, 1994) . LL growth can
occur at a steady rate but also shows non-linear changes with
intermittent leaps in growth as well as clear slowings or
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shrinkage which might be associated with catabolic stress
(Wales Sc Milner, 1987) . It is not clear whether there is a
definite periodicity as analytical techniques, such as moving
averages, used in studies looking at periodicity are prone to
aliasing when they incorporate possible outliers into the
data and produce regular periodicity where none exists
(Hermanussen, 1988(b)). More recently, highly accurate and
precise radiogrammetric studies looking at growth in rabbits
with metal pins inserted into the bone have documented a
Gaussian distribution of velocities around an intermediate
value, more indicative of continuous growth (Klein et al,
1994).
The episodic increase documented in previous studies could be
partly due to intra-observer bias leading to an inaccurately
low TE, as referred to earlier. However, the studies
performed in healthy neonates which have been done by a
process independent of observer bias have also revealed
saltatory growth (Gibson et al, 1993a, Wales & Gibson, 1994) .
D . Prediction of Long-term Growth
Early studies concentrated on studying the value of short-
term knemometric studies in predicting the long-term efficacy
of growth promoting therapy such as GH. The variability of
LLL increments and the fact that these increments cannot
reflect simultaneous growth in other parts of the skeleton,
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limit the role of knemometry in the prediction of long-term
growth. For prediction of annual height velocity, the
correlation coefficient using a 1-month increment is 0.069,
for 3 months, 0.437 and for 6 months, 0.732 (Dean et al,
1990) . To assess the effect of growth-promoting drugs an
estimated difference of 0.37mm/wk over two 6-week periods
would be necessary at a 5% level; this is equivalent to a
statural growth response of at least 6.3cm/yr (Wit et al,
1987). A study of 12 girls with Turner Syndrome treated with
GH revealed that a short-term growth response in DLL at one-
month had only a 50% positive predictive value for a six
month response in improved statural height, but had a 100%
negative predictive value (Wales & Milner, 1989) .
E . Therapeutic Intervention & Skeletal Growth
The study of short-term growth in relation to interventional
strategies which might alter normal growth could provide an
insight into the biology of the growth process as well as
documenting any adverse effects which could be alleviated by
modification of the treatment strategies. The effect of
corticosteroids on growth and bone metabolism are well known
although the pathophysiological basis is still not clearly
understood (Tonshoff et al, 1996). Suppression of LL growth
has also been documented in studies of short duration in
children treated with steroids for Crohn's Disease, asthma
and chronic neonatal lung disease (Wales & Milner, 1988,
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Wolthers & Pedersen, 1992, Bisgaard, 1993, and Gibson et al,
1993b). A pilot study looking at LLL growth of 7 children
receiving high-dose i.v. MTX and oral 6-MP following
remission induction of ALL showed some evidence of growth
retardation which was not statistically significant (Tammings
et al, 1992) . Assessment of growth factors and markers of
bone turnover might provide a better understanding of the





Section 2. The treatment of acute
lymphoblastic leukaemia
Before cure could be achieved in children with acute
lymphoblastic leukaemia (ALL), improvement of
systemic treatment led to longer periods of remission
which were accompanied by an increase in the rate of
first relapse in the central nervous system (CNS)
reported at around 50-80% (Evans et al, 1970, Price &
Johnson, 1973) the ultimate outcome of which was
death. Thus treatment protocols with the aim of
preventing the development of overt CNS leukaemia
were initiated and nowadays the combination of
multiagent chemotherapy, better supportive care and,
crucially, the addition of CNS prophylaxis, provide a
child with ALL and no adverse risk factors, a greater
than 70% chance of cure (5-yr survival) (Boring et
a 1, 1994); this ever-increasing population is,
however, at risk of long-term effects of therapy.
Although specific approaches to therapy may differ
from centre to centre, all modern treatment regimens
comprise four major elements: remission induction,
intensifica-tion/conso1idation, CNS-directed therapy,
and continuation of treatment.
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A. Remission Induction
Complete remission is defined as the absence of
clinical signs and symptoms of disease, the recovery
of normal blood cell counts, and the recovery of
normocel lular bone marrow with fewer than 5% blast
cells. Induction of remission typically involves
administration of a glucocorticoid (dexamethasone or
prednisolone), vincristine and L-asparaginase . The
need for early aggressive therapy is supported by
studies which have shown that more complete reduction
of the leukaemic clone after the first 2 weeks of
induction treatment predicts a favourable outcome
(Miller et al, 1989, Gaynon et al , 1990). With
present regimens, up to 98% of children achieve a
complete remission.
B. Intensification Chemotherapy
"Intensification" refers to strategies of systemic
chemotherapy that are more aggressive than those
employed during remission or continuation treatment
and their main aim is to retard drug resistance and
control residual leukaemia (Rivera et al, 1991) . Most
protocols specify a period soon after remission
induction when patients receive either increased
doses of agents used previously or entirely new
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agents with minimal cross-resistance. Although with
this approach improved outcome has been reported
(Clavell et al, 1986 and Gaynon et al, 19 8 8) , there
is some doubt as to the benefit of this therapeutic
strategy in low-risk groups (Camitta et al, 1980) .
The drugs used in this phase include daunorubicin,
cytarabine, etoposide as well as the drugs used in
"induction". A relatively new intensification regimen
involves the use of parenteral methotrexate (Mtx) and
6-mercaptopurine (6mp) with the assumption that
neither drug produces severe acute or long-term side
effects (Camitta et al, 19 89) . There are often more
than one period of intensification and in the current
Medical Research Council trial in the United Kingdom
(UKALLXI) there is an option for a prolonged third
period of intensification which includes treatment
with cyclophosphamide as well as the drugs listed
above.
C. Prevention of CNS Relapse
Use of cranial irradiation (XRT) and intrathecal Mtx
(itMtx), given after complete remission induc-tion is
essential as leukaemia in the CNS not only reduces
chances of cure but also increases morbidity related
to the need for intensive remission-retrieva1 therapy
(Mulhern et al, 19 89) . Concern about the adverse
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effects of XRT (Wallace & Shalet, 19 92) have led to
the replacement of XRT with age or s i z e - ad j us t ed
doses of either high-dose iv or itMtx or triple agent
i.t.chemotherapy consisting of hydrocortisone,
cytarabine and Mtx (Tubergen et al , 1993 and Pullen
et al , 19 9 3) . There is no long-term evidence that
high-dose ivMtx is as effective as XRT in terms of
CNS recurrence or chronic survival (Jenney et al,
1994) . It was recently shown that amongst
"intermediate" risk children survival, as well as
event-free survival, was better in those treated with
1800cGy instead of itMtx alone (Tubergen et al,
1993) .
D. Continuation Chemotherapy
As studies have shown that therapy lasting only for
15 months following remission was associated with a
high rate of relapse (Chessels, 1982) and that
therapy lasting for longer than 3 years did not
provide any additional benefit (Eden et al , 1991) ,
most treatment protocols discontinue all treatment
for those in whom continuous complete remission has
been achieved for two to three years. ALL is unique
amongst cancers in that it requires such prolonged
continuation treatment. This kind of treatment might
be necessary to kill the more slowly dividing
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leukaemic cells which might have been less
susceptible to earlier chemotherapy(Pinkel, 1987) or
it could simply suppress leukaemic cell growth to the
extent that naturally programmed cell death, or
apoptosis, can occur (Gale & Butturini, 1991) . The
mainstay of "continuation" treatment is a combination
of oral 6-Mp and Mtx together with intermittent
pulses of Vcr and Pred. Response to treatment with 6-
Mp and Mtx appears more favourable when the
combination is administered to the limits of
tolerance, as determined by how low the neutrophil
counts fall during treatment (Hale & Lilleyman, 1991
& Pearson et al, 1991). With no evidence of any long-
term sequelae this mode of therapy is used for all
children, including the low-risk individuals.
E . UKALL XI ( 9 2 )
The children who were studied and received treatment
for ALL followed the protocol designed for the
UKALLXI(92) trial co-ordinated by the Medical
Research Council of the United Kingdom which started
in March 1992. The aim of this trial was to compare
intensification of chemotherapy administered at
different times and to test if CNS disease
eradication can be successfully achieved without
cranial radiotherapy. The treatment period ran for a
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total duration of 2 years and included all the phases
mentioned above (Fig.2.2). Details of the treatment
regimen are presented on the schema on the following
pages. Briefly, patients were stratified by white
blood cell count on presentation for randomisation to
CNS treatment which was given immediately after
induction therapy(Weeks 1 to 4) and early
intensification (Week 5) (Fig.2.3). Another block of
(late) intensification therapy was administered at
Week 20 and patients were randomised to receive or to
not receive a further (Third) block of
intensification therapy from Week 35 to Week42
(Fig.2.4). In between these blocks of intensive
chemotherapy, and up to Week 100 following start of
therapy, patients received continuation chemotherapy
in 12 weekly cycles (Fig.2.5) . XRT at 2400cGy was
reserved for patients who had identifiable leukaemic
blasts in the CSF; hyperleukocytosis, indicating a
high risk of CNS relapse led to randomisation into
either high dose ivMtx or XRT.
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Fig.2.2 UKALLXI(92)-Summary of Treatment Regimen
and Options
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Section 3 The effect of individual drugs on
the central nervous system and
bone & collagen turnover
This chapter discusses the present evidence against
individual treatment modalities for effects on the
CNS, which may interfere with the central control of
growth, and effects on bone and collagen metabolism.
It should, however, be borne in mind that these drugs
might have altered effects when given in combination
(Mullenix et al , 1994 and Schunior et al , 1994) .
Section 6 will review studies of growth and bone &
collagen metabolism in children treated with combined
cytotoxic chemotherapy.
A. Vincristine (Vcr)
Vcr is a vinca alkaloid cytostatic drug which binds
to mitotic spindle protein and thus arrests cell
division. It also impairs axonoplasmic transport,
prevents formation of neuro-filaments and disrupts
those a1ready formed; these effects lead to
peripheral neuropathy which is dose-dependent. CSF
concentrations of Vcr are less than 1% of peripheral
levels (Johnson et al , 1973) . However, the syndrome
of inappropriate antidiuretic hormone secretion has
been reported with its use, as well as other effects
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such as confusion, hallucination and coma
(Hildebrand, 1978).In vitro studies in isolated rat
perfusion systems have shown significant inhibition
of insulin-like growth factor-I (IGF-I) production in
response to GH in the presence of Vcr (Morris, 1981) .
These studies also showed reduced uptake of (35S)-
sulphate into porcine costal cartilage in response to
IGF-I stimulation in the presence of Vcr. On the
basis of these studies, IGF-I production as well as
IGF-I action seem to be adversely affected.
B. Daunorubicin (Dnr)
Dnr is a glycosidic anthracyc1ine antibiotic which
intercalates between adjacent base pairs on a DNA
strand. Dnr does not cross the blood brain barrier
(BBB) . The porcine costal cartilage bioassay in the
presence of Dnr led to reduced uptake of (35S) and
also ( 3 H) - thymi dine . No effects were seen on IGF-I
production in the 1iver-bioassay(Morris, 1981) .
C. P r e d n i s o 1 o n e ( P r e d ) & Dexamethasone(Dxm)
These glucocorticoids cause a lysis of lymphatic
tissue mediated by surface receptors of lymphocytes
and lymphoblasts . Leukaemic lymphatic cells are
specially susceptible to this lympholytic mechanism.
The steroids have a diverse number of effects. They
44
can cross the BBB and have effects on mood, behaviour
and brain excitability (Balis et al, 1987) .
Administration of daily Pred in adults leads to a
reduction in integrated GH concentration as well as
GH production rate and this inhibition is reduced on
alternate day regimens (Thompson et al, 19 8 3) . The
inhibitory action seems to be mediated by an
enhancement of somatostatin tone resulting in poor GH
response to growth-hormone releasing hormone
stimulation (Giustina et al, 1990). This is supported
by the observation that the steroid-indueed decrease
in growth of rats can be partially reversed by
concomitant treatment with somatostatin antibodies
(Wehrenberg et al, 1990) .
Corticosteroid excess also has direct effects on the
growth plate and bone. Local administration of DXM
into one proximal tibial epiphysis significantly
reduced linear growth in growing rabbits (Baron et
al , 1992) . Morphological studies have revealed
disrupted angiogenesis in growth plate cartilage in
rabbits (Brown et al, 1990) and inhibition of
chondrocyte proliferation and cartilage matrix
production (Annefeld, 1992) in response to systemic
Dxm administration in rabbits. Studies in rats have
shown that local IGF-I transcription is reduced on
4 5
inhibiting cell replication and synthesis of
collagen and IGFs (Canalis & Avioli, 1992) . Bone
resorption is indirectly promoted by increased
sensitivity of bone cells to parathyroid hormone
(PTH) and secondary hyperparathyroidism due to
steroid-indueed renal and intestinal loss of
calcium (Gennari et al, 1984). Direct promotion of
resorption is supported by the finding that Dxm can
enhance osteoclast generation in isolated mouse
bone marrow cultures (Shuto et al, 1994).
D. Asparaginase (Asp)
Asp is an enzyme derived from Escherichia coli or
Erwinia carnotovera and hydrolyses L-asparaginine,
thereby depleting the supply of this amino acid as
well as L-glutamine which cannot be synthesised by
leukaemic cells. Although Asp does not cross the
BBB, peripheral depletion of these amino acids
results in a fall in CSF levels. Reported frequency
of CNS toxicity varies from 25%-50% and range from
lethargy, confusion to seizures and coma (Weiss et
al , 1974 ) .
E. Methotrexate (Mtx)
Mtx inhibits dihydrofo1ate-reductase by binding to
it and inhibiting the production of
tetrahydrofo1ate . This coenzyme is involved in the
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production of purines and thymidylate, depletion of
which results in the inhibition of DNA synthesis.
When given i.v. in moderate or high doses, Mtx can
reach CSF levels 1-3% of that in plasma (Bleyer &
Poplack, 1978) . Cranial irradiation as CNS-directed
prophylaxis has been replaced by i.t. or high-dose
i.v.Mtx administration in most protocols. White-
matter lesions which could represent areas of
demye1inization or micro-infarction have been
observed on magnetic resonance imaging (MRI) in
children treated by this regimen (Bakke et al,
1993, Seidel et al , 1994) . These changes could be
transient (Lien et al , 1991, Wilson et al , 1991)
but could persist as suggested by a correlation
between the presence and type of cranial
abnormalities and deterioration of
neuropsychological function after Mtx treatment
(Brouwers et al, 1985) . An association between
long-term Mtx therapy and osteoporosis and stress
fractures has also been reported (Schwartz &
Leonidas, 1984) . In some cases these fractures do
not heal until the withdrawal of Mtx (Stanisvalje &
Babcock, 1977) . The mechanism of this effect has
not been elucidated but it could be related to the
anti-folic effects of Mtx as the radiological
features of affected bones are similar to those
found in scurvy. The costal cartilage bioassay
(Morris, 1981) studying abnormalities of substrate
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uptake did not reveal any reduction in response to
IGF-I in the presence of Mtx.
F. 6-Mercaptopurine (6mp)
6mp is a hypoxanthine analogue, which after several
metabolic conversions is incorporated in DNA as a
false nucleotide, resulting in cell death. CSF
levels of 6mp are about 45% of those of plasma
during maintenance (Schouten et al, 1984) . However,
no specific neurotoxic effects have been reported.
The porcine costal cartilage bioassay in the
presence of 6mp did not lead to altered uptake of
(35S)-sulphate or (3H)-thymidine. However, IGF-I
production in response to GH in the isolated liver-
bioassay was reduced (Morris, 1981).
G. Cytosine-Arabinoside (Ara-C)
Ara-C is a pyrimidine analogue, which selectively
inhibits DNA synthesis by the incorporation of the
active metabolite Ara-C triphosphate into DNA.
Levels up to 40% of those in plasma can be reached
in the CSF if Ara-C is administered by continuous
i.v. infusion which are, however, less neurologic-
ally toxic than intermittent high doses of the drug
(Lockhart et al, 1994). The porcine costal
cartilage bioassay in the presence of 6-MP lead to
altered uptake of ( 3 H) - thymidine only. IGF-I
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production in response to GH in the isolated liver-
bioassay was minimally reduced (Morris, 1981) .
H. Cyclophosphamide (Cyclo)
Cyclo belongs to the group of nitrogen mustards
which act as alkylating agents. Only minute amounts
of Cyclo penetrate into the CSF. Nausea and
vomiting may be the result of a direct effect on
the CNS; with high doses, SIADH has been observed.
The porcine costal cartilage bioassay did not show
any major alterations in the presence of Cyclo
(Morris, 1981).
I. Etoposide (Etop)
Etop is a cytotoxic semi-synthetic
epipodophyllotoxin which acts by producing protein-
linked DNA strand breaks by inhibition of DNA
topoisomerase used in condensing or decondensing
supercoiled DNA. Neurotoxicity is rarely reported
with Etop with somnolence occurring in about 3% of
cases.
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Section 4 Markers of Growth Hormone Secretion
Optimal evaluation of GH secretion has been an important
problem in paediatric endocrine practice. Tests for GH
secretory ability need to be sensitive, specific, practical,
reproducible and safe. The traditional serum GH provocation
tests do not fulfil any of these criteria and this has
generated an interest in simple, harmless and practical
methods of measuring markers which might reflect
physiological GH secretion.
A. Urinary Growth Hormone (uGH)
The major form of GH in urine is a 22kd peptide. Most of the
secreted GH is degraded by the liver, kidneys and the
peripheral tissues and less than 0.001% of the GH secreted by
the pituitary is excreted in the urine (Baumann & Abramson,
1983); renal function can, therefore, have a profound effect
on uGH levels (Hattori et al, 1988). uGH can be measured by
prior dialysis and concentration of the urine followed by a
double-antibody radioimmunoassay with a sensitivity of
0.3ng/ml (Hansenn, 1974). More recently described methods
employing enzymelinked immunosorbent assays and immuno-
radiometric assays are sensitive down to 0.4-4pg/ml (Porquet
et al, 1992) .
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The appropriate method of expression of uGH output is
controversial. Results can be expressed by assessing timed
urine collections (ng/12hrs) based on chronological age,
weight, surface area or creatinine excretion (MacGillivray,
1993) .
Since the amount of GH present in timed urine collections
from healthy subjects is extremely small, standardisation on
the basis of age, weight, or surface area results in
considerable overlap of values between groups. Normalising
data on the basis of creatinine excretion can also lead to
significant error because creatinine is dependent on lean
body mass which changes with age, puberty and clinical state.
Due to these uncertainties, some investigators have reported
the absolute outputs of uGH in nanograms per time interval
without any standardisation steps (Albini et al, 1991,
Granada et al, 1992) .
In most studies uGH excretion correlates positively with
plasma GH concentration as assessed by physiological or
provocation tests in children who are not in advanced
puberty. However, the overlap of uGH values between normal
and short (GH-deficient and Idiopathic Short-Stature)
children precludes the test as an adequate screening test for
GH-deficiency (Albini et al, 1991). Another disadvantage of
the uGH test is its range of variability in the same child.
This results from a combination of assay variation and
variability in renal handling of GH (MacGillivray, 1993). As
minor changes in renal function can influence the variability
in consecutive uGH levels in the same subject it would be
useful to compare the renal handling of GH with other freely
filtered proteins (Skinner et al, 1993) . A further reason for
the observed variability could be that there is real
biological variation in GH secretion (Thalange et al, 1996)
but this remains to be proven. The variation error can be
reduced by collecting repeat samples (Skinner et al, 1993) .
uGH assays have not been used to gather information about
relative outputs of GH over time, nor to assess changes in
uGH in relation to therapeutic interventions aimed at
increasing or decreasing GH production. Such investigations
could provide a non-invasive method of studying abnormal
growth provided that uGH levels reflect short to medium-term
growth.
B. Insulin-Like Growth Factor I (IGF-I)
IGF-I is a 7.6kD single chain polypeptide which is regulated
by a combination of autocrine, endocrine and paracrine
factors. The major regulator of circulating IGF-I is GH and
the main site of production is the liver (Hynes et al, 1987) .
The synthesis if IGF-I by osteoblastic cells is enhanced
mostly by parathyroid hormone (PTH) and to a lesser extent by
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GH. Skeletal IGF-I also enters the circulation but whether
plasma IGF-I reflects local tissue levels is undetermined; it
is possible that the endocrine and paracrine control as well
as effects of IGF-I are distinct from each other. The actions
of IGF-I can be classified into two groups; short-term
metabolic and long-term mitogenic effects. The metabolic
effects are similar to those of insulin with negative
feedback inhibition of GH secretion. In combination with GH,
IGF-I has proliferative effects on epiphyseal chondrocytes
(Lindahl et al, 1987). Following GH-induced differentiation
of target cells, IGF-I acts to promote tissue growth by
clonal expansion. Besides its direct proliferative action,
in-vitro studies have shown that IGF-I also promotes bone and
collagen growth by promoting Type I collagen synthesis,
increased proteoglycan synthesis in chondrocytes, maturation
of the osteoblast phenotype and inhibition of skeletal-
specific collagenases (Rosen et al, 1994) . There is some
early evidence that IGF-I might be involved in osteoclast
activation, too (Slootweg et al, 1992) . In paediatric
practice, IGF-I levels have been used primarily for
evaluation of GH-secretion (Juul et al, 1994). IGF-I levels
are, however, subject to the same "overlap" problem as uGH as
discussed above. In addition, its levels do show some
circadian variation (Minuto et al, 1981) and depend on the
state of nutrition (Monaco et al, 1992).
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C. IGF Binding Proteins-3 (IGFBP-3).
The systemic and local effects of IGFs are modulated by a
group of proteins, the insulin-like growth factor binding
proteins (IGFBPs) which have a high affinity and specificity
for the IGFs. Of the six IGFBPs so far described, IGFBP3 is
the most abundant protein in serum. It is produced by most
cell types including osteoblasts and although the core
protein has a molar weight of 28.7kD, it exists in the
circulation as a 150kD complex with an acid labile 85kD
glycoprotein and one of the two IGFs (Rosen et al, 1994) .
Factors known to influence IGFBP3 levels include GH levels
and age and puberty (Blum & Ranke, 1990); unlike IGF-I,
IGFBP3 reduces only with prolonged restriction (Young et al,
1992) . Release of IGF from the complex is thought to occur
following a lowering in pH and is mediated by IGFBP proteases
(Clemmons et al, 1986). IGFBP3, therefore, seems to inhibit
unnecessary insulin-like activity, prolong the half-life of
IGFs and enhance the biological response of target tissues to
IGFs by directing them to particular cell types.
The value of IGFBP3 as a marker for GH secretion has only
recently been studied and whether it is a more reliable
indicator than IGF-I is still debated. As IGFBP3 levels alter
IGF-I bioavailability they might reflect GH secretion better
than IGFI; the methodology involved in IGF radioimmunoassay
needs preliminary IGFBP extraction which if not performed
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optimally can lead to inaccurate results (Brier et al, 1991);
the IGFBP3 assay has a higher reference range than the IGF-I
assay, making the assay more sensitive to the detection of
decreases in GH secretion (Blum et al, 1990). It is possible
that changes in IGF-I levels are more sensitive to GH
secretion, explaining the circadian rhythm, and IGFBP
provides a more integrated measure of GH secretion. Finally,
there is some evidence that IGFBP3 levels are more
reproducible when performed repeatedly as compared to IGFI
(Blum et al, 1993). However, it has recently been shown that
IGFBP3 measurement might be as reliable as IGFI in assessing
GH secretion (Hasegawa et al, 1994).
Section 5. Biochemical markers of bone & collagen
turnover
Somatic growth involves synthesis and depostion of collagen
and the study of biochemical markers of bone and collagen
turnover provides the means of further understanding the
physiology of growth as well as the mechanism by which growth
could be disrupted by specific pathological processes. This
section will consist of a brief review of some of the markers
which have been used in these studies.
A . The Basic Multicellular Unit
Sequential replacement of old bone with new occurs within a
defined quantum of bone, the basic multicellular unit (BMU).
The cycle begins with multinucleated osteoclasts which
originate from haemopoietic stem cells. These cells cause
bone dissolution by release of protons and proteases. 5 to 7
days of resorption by the osteoclasts produce a resorption
lacuna. After a short quiescent phase, bone formation in this
area proceeds over a span of approximately 100 days.
Mesenchymal-derived osteoblasts synthesize the new bone by
forming an organic matrix which is later mineralized. The
frequency of BMU activation is dependent on the nature of the
activating signal(eg. hormones, gonadal steroids, cytokines
and growth factors) and possibly, skeletal architecture
(Parfitt et al, 1996). The time span mentioned above is that
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for post-pubertal bone and it is possible that it differs in
growing children and is variable from site to site. The
markers of bone and collagen turnover are illustrated in
Figure 2.6.
B . Markers of Bone Formation
The developmental sequence of an osteoblastic cell phenotype
has been divided into three consecutive phases:
proliferation, extracellular maturation and mineraliza-tion
(Stein et al, 1990) . Mesenchymal cells committed to the
osteoblast lineage only produce Type I Collagen which occurs
early during the proliferation of the precursor cells. The
expression of alkaline phosphatase (ALP) starts immediately
after cessation of cell proliferation, reaches a maximum
during the phase of matrix maturation and declines as matrix
mineralization commences. Among the genes expressed at this
point are those for the calcium binding proteins, osteocalcin
and osteopontin.
i . Procollagen Type I Carboxy-Terminal Propeptide
( PICP ) .
Type I collagen, the most abundant collagen in the body and
is present in most tissues but especially bone, is
synthesized as a larger protein, type I procollagen. The
extra material is present at the carboxy as well as the amino
terminal of the protein molecule and is necessary for
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preventing premature association of the molecules into
collagen fibrils. These extension domains are cleaved on
extracellular secretion of the procollagen. PICP is not
metabolised but rapidly cleared intact by the liver
reticuloendothelial cells. Serum PICP can be measured by a
commercial radioimmunoassay (Melko et al, 1990) and its
concentration is closely related to the rate of the
histomorphometrically assessed bone matrix formation (Eriksen
et al, 1993). PICP maybe a good indicator for catch-up growth
after severe disease in children (Hyams et al, 1989) .
Circadian variation has been noticed in PICP levels and a
positive relationship between 24hr PICP levels and GH
secretion and growth velocity (Saggese et al, 1994).
ii. Bone Alkaline Phosphatase (bALP)
The function of this enzyme is not known with certainty but
it is associated with the plasma membrane of the osteoblast,
which buds out to form the matrix vesicles seen in developing
bone. It may be involved in extracellular breakdown of
pyrophosphate, a potent inhibitor of calcium phosphate
deposition. Total ALP (tALP) activity levels measured by
simple colorimetry correlates with bone formation rate but a
drawback of this method relates to the presence of isoenzymes
originating from tissues other than bone. This is less of a
problem in healthy children in whom most of the tALP is
derived from bone. The activity of the liver isoform might be
58
affected by drugs affecting hepatic function and at times of
impaired growth it might be appropriate to measure bALP
specifically by methods such as wheat germ affinity
electrophoresis (Crofton, 1992) or immunoradiometric assay
(Gomez et al, 1995) . It is not yet clear, however, whether
the bALP measurements give significant new information over
the total activity.
C . Markers of Bone Resorption
Osteoclasts express a number of lysosomal enzymes and
proteins which produce an acidic environment and promote bone
resorption. Breakdown of collagen fibres results in a mixture
of peptides and amino acids. The regions of the collagen
molecule that participate in covalent cross-linking between
molecules seem to be less susceptible to the action of these
enzymes.
i. Pyridinoline (PYD) & Deoxypyridinoline (DPD)
Collagen molecules in fibrils are cross-linked by pyridinium
structures which are heterogeneous with respect to their
degree of hydroxylation and glycosylation. PYD is found in
fibrillar (mature) collagen from several tissues, including
soft tissues, but it is particularly characteristic of Type
II collagen of cartilage and the Type I of bone and dentin.
Due to the large amount of bone collagen in humans, most of
the PYD detected in the urine is derived from bone. DPD is
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another variant which almost exclusively originates from bone
collagen. The above pyridinium crosslinks can be
simultaneously measured by high pressure liquid
chromatography. There is generally good correlation between
accelerated bone turnover and the urinary excretion of the
cross-links (Seibel et al, 1992).
ii. Cross-linked Carboxyterminal Telopeptide of Type
I Collagen (ICTP)
Inter and intra-crosslinking between collagen molecules
occurs at the short non-helical ends of the collagen
molecules known as telopeptides and ICTP is liberated from
the carboxyterminal end of Type I collagen when the latter is
degraded. ICTP can be assayed from plasma using a
commercially available radioimmunoassay and preliminary data
suggests that it is a marker of bone resorption (Eriksen et
al, 1993) .
D . Bone-Exclusive Markers of Collagen Synthesis
The above markers are all related to bone collagen synthesis
or breakdown. Procollagen Type III Amino-Terminal
Propeptide (PIIINP) is cleaved off during the synthesis of
Type III collagen in a fashion similar to PICP. Type III
collagen is present in almost all tissues except bone and
cartilage. The serum concentration measurable by a radio¬
immunoassay has been shown to correlate with the somatic
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growth rate in healthy children whereas PICP levels reflect
bone and linear growth (Graham 1989, Trivedi et al, 1991).
Circadian variation, when studied, was not evident in
relation to PIIINP levels (Sagesse et al, 1994). Simultaneous
measurement of both PICP and PIIINP should give an indication
of the relative amount of both bone and soft-tissue collagen
formation.
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Fig.2.6 Markers of Bone and Collagen Turnover
Type III Collagen Formation
Aminoterminal Propeptide




















Section 6 Growth and bone metabolism during
cytotoxic chemotherapy
The effects of XRT on growth have now been extensively
studied and well documented (Wallace & Shalet, 1992) and this
mode of treatment is now only used in a small number with CNS
disease or at a high risk of CNS-relapse. The effects of
cytotoxic chemotherapy (CT) on growth are less well
understood. This section will review the present literature
on the effect of CT on growth and bone metabolism.
A . Cytotoxic Chemotherapy & Growth
The first indication that CT by itself might have a harmful
effect on growth in children with ALL, was the report that a
more intensive chemotherapeutic regimen, but a similar
radiotherapy regimen, showed worse growth retardation (Kirk
et al, 1987, Clayton et al, 1988) . The second study also
showed that catch-up growth following the end of CT did not
compensate completely for the earlier fall in height (Ht)
standard deviation scores (SDS). Thun-Hohenstein et al (1992)
compared children who received treatment with one of two
protocols of different intensity (Ber1in-Frankfurt-Munster
(BFM) or non-BFM), and reported that those receiving the less
intensive CT showed less growth impairment. The intensive
treatment group received significantly more cyclophosphamide,
anthracyclines, nitrosureas and vincristine.
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The initial decline in HT SDS during the period of treatment
is felt to be due to CT rather than XRT (Hokken-Koelega et
al, 1993). This study also showed that catch-up growth which
only started after CT ended restored CT-only children to
their original HtSDS 5 years after diagnosis and CT, by
itself, only had a temporary effect on growth.
In theory, CT can affect the mechanisms controlling growth at
different points as discussed before. Minor white-matter
lesions have been seen on MRI in children who have received
CT only regimens for ALL (Bakke et al, 1993) ; there is a
possibility that these lesions could affect GH secretion if
they occurred around the hypothalamo-pituitary area, albeit
temporarily. Physiological GH secretion profiles during
investigation have been found to be satisfactory, except in
one case where it was profoundly depressed and was related to
high-dose DXM treatment; this was the only child investigated
on Dxm treatment (Marky et al, 1991) . Another study looking
at serial changes in the GH-IGF axis in children receiving
craniospinal irradiation for brain tumours showed a transient
decrease in IGF-1 and IGFBP-3 levels in the presence of
normal GH levels in the first 6 months of therapy when
treatment was particularly intensive (Nivot et al, 1994) . The
changes coincided with a fall in BMI and plasma concentration
of total proteins indicating a defective nutritional status
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and the possibility of a transient GH resistant state.
Hepatic dysfunction which might be due to the CT used could
also contribute to reduced levels of IGF-1 production.
B. Bone Metabolism and Chemotherapy
Although children with ALL might present with osteoporosis at
diagnosis it has become evident that osteoporosis of variable
severity can also occur during treatment (Schwartz, 1984,
D'Angelo, 1989) and could be related to the effects of CT.
Following completion of CT for ALL, Gilsanz et al (1990)
found significant reduction of bone mineral density in only
those children who received XRT. Nussey et al (1994) related
reduced bone mineral density in long-term survivors of XRT
for ALL to GH deficiency. Another study raised the question
whether altered calcium and magnesium homeostasis in children
on treatment is a possible cause of abnormal bone turnover
(Atkinson et al, 1989) .
Further evidence of the involvement of CT came from a study
looking at final Ht and sitting height (SH) in survivors of
childhood solid tumours. The males who had received both CT
and radiotherapy to the spine had a greater decrement in SH,
but no association was found between radiation therapy to the
spine without CT and subsequent growth of the spine
(Makipernaa, 19 90) .
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CHAPTER THREE
SHORT-TERM CHANGES IN LOWER LEG LENGTH IN HEALTHY
INDIVIDUALS
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Short-term growth studies using knemometry have revealed a
saltatory pattern of growth in children while total body
length or stature measurement reveals a more continuous
pattern. The precision of the technique is likely to
dictate the pattern of growth and any measurement bias
will affect that precision. The first section of this
chapter investigates the presence of observer bias as well
as the presence of any learning curve for the technique.
The pattern of growth in healthy "normally-growing"
children remains controversial and before any studies of
interven-tional therapy, it is important to document the
nature of this growth in healthy children as performed by
the same group of measurers and analysed uniformly. This
group of children would provide some reference data
against which groups of other children on treatment can be
compared but they would not act as strict controls,
primarily as they do not suffer from any illness. In order
to study changes in LLL which might be artefactual a group
of fully grown adults was also studied.
The relationship between changes in LLL and weight is
described in Section 2; Section 3 studies relationships
between fluctuations in LLL and concurrent excretion of
urinary Growth Hormone. Utilising this information the
pattern of growth in children is discussed in Section 4.
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Section 1. Comparison of two different techniques
of knemometry
A. Introduction
The method of knemometry in children as described by the
original investigators is now universally accepted (Valk et
al, 1983) . Knemometry is easy to learn and although some
investigators have suggested that there should be a learning
period (Hermanussen et al, 1988), there are no data available
evaluating how long it takes to become proficient. Using the
Valk knemometer, which has an accuracy of 0.1mm, the technical
error (the mean standard deviation in a series of n
independent measurements)(TE) has ranged between 0.09mm to
0.16mm in previous studies (Hermanussen, 1988) . As no
modifications of the original method have been described it is
likely that the measurer in previously reported studies is not
blind to previous estimations in the set from which each
measurement is derived.
Methods which employ "blind" lower-leg length estimations have
been developed for the neonatal knemometer where the
estimations are printed at some distance from the measurer
(Gibson et al, 1993a) . The TE has been reported to be higher
at 0.3-0.5mm and a learning curve was also found using this
method.
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In this study a simple modification of the original technique,
designed to reduce the intra-observer bias, was
investigated. This technique was also used to evaluate the
presence of a learning period for the technique, information
which is important for prospective users.
B. Patients & Methods
Over the period between May 1993 and August 1994, 50 children
aged 4.2-12.8 years and 8 healthy adults had knemometry
performed. The children consisted of 26 healthy volunteers
from a neighbouring primary school, 18 children on cytotoxic
chemotherapy and 6 children with cystic fibrosis. Individual
children were measured at the same time of the day (within an
hour's time interval from the first measurement), on a weekly
basis, for periods ranging from one to ten months, depending
on the group. The adults were measured in the last two months
of the study. Measurements were performed at either one-weekly
or two-weekly intervals.
Each measurement was derived from a set of 4 "estimations";
the most deviant of the 4 estimations was eliminated and the
mean of the rest was calculated to provide a "measurement"
(Wales 5c Milner, 1987) .
Measurements were performed using two methods; the Original
Method (OM) was performed as described by Hermanussen (1988)
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in Chapter One; Section 1(A) . The Random Zero Method (RM)
differed from OM in that the baseline reading on the preset
meter was altered by the measurer before each estimation when
the measuring platform was resting at zero. The preset meter
was covered with a piece of paper when the alteration was made
so that the measurer was not aware of the baseline reading
until the end of the estimation. Each estimation was recorded
as a set of two readings and deduction of the baseline from
the actual digital read-out provided the estimation.
C. Statistical Analysis
The technical error (TE) for each measurement was derived from
the standard deviation of the set of 3 estimations which make
up each measurement as described in "Methods". The TE and
coefficient of variation (CV) for each measurement were
calculated and grouped with that of other measurements
performed in the same month. The overall average TE and CV of
the two groups (OM & RM) were presented as median values with
their respective 5th and 95th percentile values (P5 & P95) .
The Wilcoxon Signed Rank test was used as a non-parametric
test to compare differences between groups.
D. Results
413 measurements were performed over the 10-month period; the
RM group consisted of 314 measurements and the OM group
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consisted of 99. The monthly breakdown of these measurements
is detailed in Table 3.1.
Mean lower leg length velocity in the children was 0.39mm/wk
(95%CI 0.26-0.53). The mean fluctuation in leg length which
was calculated by transforming all the velocities into
positive values before obtaining the mean was 0.86mm/wk (95%CI
0.76-0.95) . This value provides an idea of the amount of
change per week that can be detected irrespective of whether
it represents an acceleration or deceleration.
Median TE in the RM and OM group was 0.15mm ( P5 - 0 , P9 5-0 . 6 5 )
and 0.11mm (P5-0,P95-0.37), respectively. Median CV in the RM
group was 0.06% (P5-0,P95-0.21), not significantly different
than 0.06% (P5-0, P95-0.16) which was the CV in the OM group.
Adults were measured in the last 2 months of the study period
by the Random Zero method only. Median TE was 0.36mm (P5-
0,P95-0.7) in April and 0.12mm (P5-0,P95-0.58) in May.
TE and CV reduced in both groups over the period of study
(Table 3.2). To analyse any trend the values for the September
and October subgroups in the RM group were excluded from
evaluation as they consisted of relatively small samples, as
was the November sub-group of the OM group. The TE reduced
over the first 4 months when RM was used on a substantial
number of occasions (Table 3.2).
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Differences of TE and CV between consecutive period of
measurements did not reach significance because of the wide
distribution of the values (Fig.3.1). However, grouping
together the TE values for the first 4 months (Nov,Dec,Jan,
Feb) revealed a median value of 0.2mm (P5-0.05, P95-0.87)
which was significantly higher than the TE for the following 3
months at 0.15mm (P5-0,P95-0.55) (p=0.04, WSR) .
E. Discussion
The physiology of short-term changes in human growth is still
poorly understood. Although instruments such as the knemometer
might shed light on changes not very far from the cellular
level, their limitations as well as their advantages must be
thoroughly assessed. Knemometry, as performed traditionally,
is subject to intra-observer bias which arises as the measurer
is aware of the previous estimation in the series. A reported
TE of 0.09mm (Hermanussen, 1988) is comparable to more precise
techniques such as kyniklometry (Hermanussen et al, 1992) in
which reproducible estimations are more likely due to better
localisation of reference points of measurement.
The RM technique described in this study eliminates the
observer bias very simply. It can be performed without any
structural modification to the original knemometer. However,
there is one extra step: deducting the baseline reading from
the initial estimation to provide the real estimation.
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Another advantage of RM is that it provides a better guide to
the length of the training period alluded to in previous
studies (Hermanussen et al, 1988) . We saw a trend towards
lower TE in the RM as well as the OM groups but this was only
significant for the TE values in the former group. This trend
might have become statistically significant by the high
outlying values at the beginning of the study but the fact
that there were more TE values near zero by the end of the
study support the suggestion of a real learning curve
(Fig. 3.1) . The lower TE in the last 2 months were not due to
the introduction of adults into the study as the TE for that
specific sub-group was slightly higher than the overall value
for that month. The low TE values for the first two months in
the RM group were unrepresentative as the sample size was
small and the RM measurements were also being performed with
extra care as it was a newly introduced method. Subjectively,
RM took much longer initially than in the latter months.
On the basis of our results we would recommend a period of 3
to 4 months for learning if the knemometer is used as
frequently as described above. By using RM, each operator can
also evaluate their own technique looking for an improvement
and subsequent plateauing of the TE. To improve the
measurement process further, it would be helpful for the
operator if the knemometer could be electronically adapted so
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that the series of estimates could be stored, the most deviant
estimate omitted and a TE calculated instantly. If the latter
is above an arbitrary limit, then there is scope to repeat the
measurements immediately.
To summarise, the Random Zero Method reduces observer bias on
the part of the measurer but does have a higher TE than
reported before. This will clearly have implications on
interpreting patterns of short-term growth with multiple
fluctuations which might well be an artefact of measurement
rather than a real phenomenon. The method also allows
independent evaluation of operator proficiency. The knowledge
of the length of the training period would help new
investigators who are designing studies involving knemometry
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Table 3.1. Distribution of measurements according to
method (Random Zero vs. Original) and month of study.














Apr 39 (10) 0
Mav 110 (60) 0
Total 314 99
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Table 3.2 Median monthly Technical Error(TE) and
Coefficient of Variation(CV) of measurements performed by
the Original Method(OM) and the Random Zero Method
(RM).5th and 95th Percentile values in parantheses.






















































Fig.3.1 Scattergram of individual TE values
the random zero method(A) and the original
method(B) plotted in chronological fashion.
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Section 2. The Relationship of Short-term changes
in Lower Leg Length and Body Weight.
A. Introduction
As the knemometer measures the complete lower leg, it is
possible that these changes may represent alterations in the
composition of subcutaneous tissue, as well as changes in
bone and cartilage turnover and growth at the cellular level.
Previous studies have shown anecdotal evidence of an inverse
as well as a direct relationship between LLL and weight
(Hermanussen et al, 1988, Seidel et al, 1991).
As the knemometer is increasingly being used to study short-
term changes in LLL in conditions associated with substantial
weight changes (Wales & Milner, 1988) it is important to
delineate clearly the relationship of weight to LLL. This
study investigates this association by documenting LLL and
weight changes in a group of healthy children and adults.
B. Subjects & Methods
Between May 1993 and August 1994, 26 pre-pubertal children
(Grp A) aged 4.2-10yrs (M:F, 12:14) and 9 healthy adults aged
29-39yrs (M:F, 5:4) had lower leg and weight measurements.
Individual children were measured at the same time of the
day, on a weekly basis for 12 weeks. In 7 adults (Grp B)
knemometry was performed daily, twice a day, about 8 hours
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apart for 6 weeks; in the remaining 2 (Grp C) who were both
women, measurements were performed once, three days a week,
for a period of 8 months. During the study, one of the Group
C subjects became pregnant. All the other women had regular
menstrual periods.
Knemometry was performed as previously described (Chapter 3;
Section 2(B)) . Subjects in Group A and B were measured by
myself whereas those in Group C were measured by 2 other
observers as well as myself. Weight was recorded with
standardised clothing on the same Avery Scales with an
accuracy of 0.05kg and a standard deviation of 0.05kg from the
mean for 3 repeated measurements. All measurements were
performed at approximately the same time of day and to
facilitate the enlistment of subjects standardisation for
ingestion, micturition and defecation was not instituted.
C. Statistical Analysis
LLL changes were expressed as LLL velocity (LLLv) as well as
fluctuations (LLLf) which represent the relative and the
absolute amount of change that can be detected between
consecutive measurements, respectively. Body weight was also
similarly calculated. In Grp A, the changes were expressed
over weekly intervals and in Grp B & C, the changes were
expressed over daily intervals. Some Group A measurements
were performed at 2-weekly intervals. In Grp B & C, data
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analysed for assessing change consisted only of measurements
performed on consecutive days. Precision of knemometric
measurements was expressed as TE. Normally distributed data
was described by mean value and 95% Confidence Interval
(95%CI) whereas skewed data was described by median value and
5th and 95th Percentile values (P5, P95). Spearman's
correlation coefficient was used to assess any association
between variables. Inter-group differences were assessed by
the Wilcoxon Signed Rank (WSR) test.
D. Results
Measurements & Technical Error
241 measurements were performed in Grp A, 110 pairs in Grp B
and 123 in Grp C. The Median TE in children (Grp A) was
0.15mm (P5-0,P95-0.58) and in adults (Grp B & C) was 0.12mm
(P5-0,P95-0.58) .
LLL and BW Changes in Group A - Children
Mean derived LLLv was 0.39mm/wk (95%CI,0.26-0.52) and mean
derived BWv was 0.08kg/wk (95%CI,0.01-0.13) . Mean LLLf was
0.83mm/wk (95%CI,0.74 - 0 . 91) and mean BWf was 0.26kg/wk
( 95%CI,0.23-0.29) . The median overall change in LLL and BW
from the start to the end of the study was 4.8mm (range, 2.4-
10.8) and -0.6kg (range,-1.4-0.5). There were no significant
differences between the two sexes in the group. There was
some evidence for a positive (Fig. 3.2) and none for an
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inverse relationship between BWv and LLLv in individual
subjects (Fig.3.3). The positive relationship was also
evident on cumulative analysis of the data (Fig.3.4).
LLL and BW Changes in Group B - Adults
Twice a day measurements in these adults revealed a
significant amount of intra-daily variation in 2 individuals;
in one, there was an increment (Table 3.3). For longitudinal
velocity and fluctuation analysis, the mean of each day's
measurement in every individual was used. Mean derived LLLv
was 0.07mm/day (9 5%CI,-0.03-0.16) and mean derived BWv was
-0.02kg/day (95%CI,-0.06 - 0 . 03) . There was no inter-sex
difference. However, median LLLf was higher in women at
0.16mm (P5-0,P95-0.7) as compared to 0.1mm (P5-0,P95-0.48) in
men (p =0.02) . This was also true for median BWf which was
0.15kg (P5-0,P95-0.54) as compared to 0.1kg (P5-0,P95-0.5) in
men (p=0.04) . The median overall change in LLL and BW from
the start to the end of the study was,-0.05mm (range,-0.9-
2.6) and -0.23kg (range,-1.7-0.9). There was no evidence of a
temporal relationship between BW and LLL changes in the
adults.
LLL and BW Changes in Group C - Pregnancy Data
Fig. 3.5 displays the changes in LLL and BW seen in the 2
subjects in this group. As evident in Grp B individuals,
there was no significant relationship between day-to-day
variation in BW and LLL in either individual. However, over
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the duration of the pregnancy LLL reduced while BW increased
until a point was reached (beginning of 3rd trimester, in
this case) when LLL started to increase; this increase
coincided with the appearance of leg oedema associated with
the pregnancy.
E. Discussion
Changes in lower leg length as assessed by the knemometer are
likely to be multifactorial. While actual growth and
remodelling of the cellular components of the leg must
contribute, it is likely that some of these changes are due
to measurement error (previous section) as well as other
physiological factors such as gravity and body weight
(Hermanussen et al, 1988).
The effect of body weight changes on LLL was briefly
described by Hermanussen as a weak direct relationship when
data from different children were analysed cumulatively
(Hermanussen et al, 1988). Anecdotal evidence for an inverse
relationship between the two variables was reported by Seidel
•et al (1991) in a child with chronic renal failure whose LLL
increased after a big weight loss following dialysis.
The cohort of healthy children in our study had a LLLv
comparable to that in previous studies and their weight gain
over the study period was not remarkable. In support of
Hermanussen et al (1988), there was a weak but significant
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relationship between the cumulated data LLL and BW change.
However, more importantly, we have also showed a significant
direct relationship in some of the individual sets of data
and the absence of a negative relationship in any of the
children. A failure to show any relationship in the other
subjects could be due to the small individual datasets. We
did not assess intra-daily variation in our cohort as this
has been shown before (Valk et al, 1983) and would have
required an extraordinary level of co-operation from the
young subjects during their schooldays.
Although the LLL and BW did not change substantially from the
start to the end of the study in adults, a significant amount
of day-to-day fluctuation was evident in both parameters,
being more pronounced in the women. Unlike previous reports
of intra-daily reduction in LLL in children, the cohort of
adults did not all show a consistent reduction in LLL over
the day while following a normal daily routine. Like the
children in Group A, none of the Group B adults gained a
substantial amount of weight over the duration of the study.
A significant reduction in LLL was, however, seen in the
subject who became pregnant and this was accompanied by a
large weight gain.
Magnetic resonance imaging of the intervertebral discs in
adults has revealed diurnal changes in size related to
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changes in the water content of the discs(Paajanen et al,
1994). Hydration is a major determinant of short-term changes
in weight and would affect subcutaneous tissue and can affect
cartilage/epiphyseal thickness. It is quite likely that the
positive relationship between changes in weight and lower leg
length seen in some of the children in this study was due to
alteration in hydration level. The failure to see such
changes, as well as the absence of universal intradaily
reduction is most likely due to a relative lack of
cartilaginous tissue in the lower leg of adults. In a
previous study, we were unable to show a temporal
relationship between body weight and lower leg length changes
in adults. Our finding of a higher amount of day-to-day
fluctuation in LLL and BW in menstruating female subjects as
compared to the male subjects could be due to changes in
tissue fluid composition. Recent evidence showing consistent
patterns of perimenstrual growth hormone secretion (Thakore &
Dinan, 1995) raises the possibility that some of these
changes seen on knemometry might reflect subtle alterations
in skeletal remodelling. This, however, can only be confirmed
by further studies of short-term growth with simultaneous
measurement of markers of growth hormone secretion and bone
turnover.
In summary, changes in LLL are likely to be positively
related to changes in body weight when the latter are only
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modest in magnitude. However, greater sustained increases in
weight are likely to have an opposite effect on LLL due to
direct compression of the lower leg. Due consideration of
body weight is essential in longitudinal studies of LLL
changes, specially in conditions which are associated with
significant changes in body weight.
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Table 3 .3 . Intradaily changes in Lower Leg Length(mm) in
adults in Group B. Subjects marked with an asterisk are
female.
Subject AM PM WSR
(1SD) (1SD)
A * 405.5 404.7 p=0.009
(0.57) (0.59)
B 439.5 439.6 NS
(0.59) (0.69)
C 444.9 445.4 NS
(1.09) (0.59)
D 424.6 425.1 p=0.04
(0.49) (0.33)
E 445.2 445.4 NS
(0.36) (0.38)
F 413.5 413.3 NS
(0.63) (0.24)
G * 383.1 382.7 NS
(0.29) (0.29)
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Fig.3.2 LLL(mm) and Body Weight(kg) changes in
some individuals in Group A
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Fig.3.3 Correlation coefficients of the variables
LLL(mm) and Weight(kg) in individual subjects A-Z
in Group A. Rear darkly shaded bars represent value
of the correlation coefficient(r2) and front bars
represent probability(p) value. The r2 value of
subjects with asterisk have a p-value less
than 0.05.
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Fig.3.4 Scattergram of cumulative data from Group A
showing the relationship between LLL(mm) and Body Wt(kg).
n = 251 r 2 =0.12 p=0.0001
LLLV(mm/wk)
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Fig 3.5 Changes in LLL(mm,broken line) and Body
Weight(kg)from baseline seen in the pregnant
(bottom panel)and the non-pregnant(top panel)




Section 3. The Relationship of Short-term Changes
in LLL and Urinary Growth Hormone
Excretion
A. Introduction
Short-term growth studies have revealed an intradaily rhythm
in LLL changes where the length is maximum in the morning and
falls over the first half of the day reaching a plateau
subsequently (Valk et al, 1983) . This variability has been
shown to relate to the duration of maintaining the erect
posture and the reduction of LLL is felt to be due to weight-
bearing on the compressible components of the lower leg
(Hermanussen et al, 1988) . Another possible factor
contributing to this intradaily rhythm could be a diurnal
variation in skeletal growth at the epiphyseal level related
to GH secretion which is maximal during the night.
Osteoblastic activity such as osteocalcin and PICP
(carboxyterminal propeptide of Type I procollagen) display a
circadian variation in serum concentration dependent on GH
secretion (Saggesse et al, 1994). uGh measurements may have a
role in studying the physiology of growth and it has recently
been shown that nightly uGH excretion can also vary in a
pulsatile fashion (Thalange et al, 1996).
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The aim of this study was to investigate whether the changes
in LLL corresponded with changes in GH production as assessed
by overnight uGH excretion.
B. Subjects & Method
Over a period of 4 weeks in June 1994, measurements were
performed at the Royal Hospital for Sick Children, Edinburgh
on every weekday in a group of 4 healthy children from a
neighbouring school.
LLL was measured with the Valk childhood knemometer as
described before (Chapter Two: Section 1(b)) by the Random
Zero Method. Measurements were all performed by one measurer
(SFA).
Subjects were instructed to refrain from any vigorous physical
activity for 2 hours before the measurements and were allowed
to miss any planned physical exercise at school. Careful
record of their bedtime, rising time and general well-being
was kept. All 4 subjects were recruited for a 4 week period
with an option for carrying on for a further 4 weeks.
Urine for uGH assay was collected as a timed overnight sample
over a 12 hr period. 0.1% BSA was added to the sample at the
end of the 12 hr collection period. 1% Thiomersal was added to
the sample at midday prior to freezing at -20°C. Samples were
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analysed in subject batches at the end of the study. uGH was
assayed using the Novo Nordisk Novoclone amplified enzyme
immunoassay (between-batch CV <12% from 9-28ng/l).
C. Statistical Analysis
LLL was expressed in millimetres (mm) and LLLV was derived
from the change in length from the previous day of
measurement and expressed as mm/day (LLLV^) . LLLV was also
derived for the overall study period from the LLL at baseline
and at the end of the study and expressed as LLLVW in mm/wk.
The precision of knemometric measurements was expressed as
the TE representing 1SD from the mean of 3 repeated estimates
of LLL obtained as described above. The total body height of
the subjects was standardised for age and sex and expressed
as Standard Deviation Scores (SDS). Considerable controversy
exists as to the best method of standardising uGh
levels (Moreira-Andres et al, 1993) and in this study they
were expressed as total uGh excreted (uGH*-) over 12 hours
(ng/12 hours) as well as the concentration of uGH (uGHc)
excreted (ng/1). Relationship between the two continuous
variables of uGH excreted & LLLV^ was assessed by calculating
the correlation coefficient and the significance of any




Details of the 4 subjects are presented in Table 3.4. Two
children were from the same family and two were in the same
class at school. The children remained generally well during
the study period and their bedtime and rising time in the
morning did not vary by more than 1 hour. All 4 children
declined the offer to continue for a further 4 weeks and the
primary deterrent was the restriction of physical activity.
Knemometry was performed on every weekday and, therefore, on
20 occasions in each child. The mean TE of the measurements
was 0.18mm (95%CI,0.16-0.22). The mean LLL fluctuation which
represents the amount of change of LLL irrespective of
whether it is an acceleration or a deceleration was 0.37mm
(95%CI, 0.29-0.45) and significantly higher than the mean TE
(p=0.0001).
Overnight samples for uGH assay were collected on 18
occasions by subject A and on 17 occasions by B, C & D. As a
group the children had a mean LLLVW of 0.52mm/wk (range,0.38-
0.78) and a mean LLLV^ of 0.08mm/day (r,0.01-0.18) . Subject B
who was the tallest of the four subjects (Table 3.4) had the
highest LLLVW as well as LLLV^ but this was not significantly
different from the rest of the group (Fig.3.6). Mean uGHc for
the group was 8.9ng/l (r, 3.9-13.3) and the mean uGHt was
1.8ng (r,1.1-2.4). uGH excretion varied widely between, as
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well as within, the subjects (Fig.3.7) . Subject B had the
lowest uGH excretion and his excretion pattern was the most
consistent as suggested by the small confidence limits in
Fig.3.7.
Although the pattern of variation of uGh excretion between
the subjects was similar when excretion was expressed as
concentration or absolute amount of uGh, the differences
between children were more significant when the former method
was employed (Fig.3.7). The mean day-to-day Coefficient of
Variation of uGHc for the whole group was 55% (r,32-93) and
56% (r,38-89) for uGH^1.
Fig.3.8 shows the temporal relationship between uGH^ and
LLLV^. Although there was no significant correlation between
these two variables, visual examination of the patterns shows
a possible temporal association at times in Subjects A, C &
D. The mean 12hr uGHc amounted to 1.5ng ( 95%CI,1.2-1.8) when
the LLLV^ was negative and 1.9ng (95%CI,1.4-2.4) when the
LLLV^ was positive in nature; these differences did not reach
significance.
E. Discussion
This preliminary study investigating the relationship of
short-term growth patterns to overnight GH secretion as
assessed by uGH levels was limited to 4 weeks primarily
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because the children felt that restriction of their physical
activities for the first half of the day before knemometry
was a major hindrance. Nevertheless the study provided some
important information about the parameters assessed.
The knemometer can be used to assess daily fluctuations of
LLL in healthy children as significant LLL changes were
evident from day to day in all four subjects. However, no
discernible pattern of change was evident over the four
weeks. As the leg incorporates soft-tissue as well as bone,
one can speculate that the changes seen in LLLV^- are most
likely to represent a combination of changes of which some,
such as hydration, are transient and some, such as epiphyseal
growth, are permanent. It is for this reason some researchers
have advocated the use of the term "fluctuations" rather than
"velocity" to describe the changes in LLL when assessed over
a short period (Hermanussen, 1988).
Our study reinforces the view that healthy children can
excrete a highly variable amount of uGH from day to day. This
variability was also evident in Thalange et al 's study (1996)
but interestingly they only rarely encountered a value below
their cut-off value for differentiating normal children from
those with GH deficiency. Previous studies at our centre
using the same uGH assay have shown that timed overnight uGHc
reflected nocturnal plasma GH profiles(Stirling et al, 1993).
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These studies have also provided a cut-off value of around
9ng/l (Stirling, personal communication) with some overlap as
encountered in previous studies (Moreira-Andres et al, 1993) .
It is, therefore, interesting to see that Subject B who was
growing the fastest had consistently low levels of uGH
excretion and was constantly below our present cut-off value
for "normality"; subjects A and D also had a substantial
number of uGH values below 9ng/l (Fig.3.7).
Serial values of uGH can be highly variable and although this
may be due to true biological variability in GH secretion or
bioavailability controlled by proteins such as the IGFBPs
(Blum & Ranke, 1993), the variability can also be artefactual
due to alterations in renal clearance of GH (Skinner et al,
1993) or inconsistencies in handling the urine sample. All
the subjects and their parents were instructed on the
collection method and had instruction sheets with the
collection kits. Following the uGH assays the participants
were again contacted to check their technique and this was
recalled correctly by all four. Urinary creatinine was not
measured; although there was some variation of body height
amongst the subjects and Subject B with the lowest uGH levels
was the tallest, all the children were prepubertal.
Expression of uGH data as concentration or as absolute mass
did not alter the coefficient of variation of repeated
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samples in our group of subjects. Expression as mass did,
however, reduce the degree of intersubject variability.
There was a temporal relationship between uGH excretion and
the nature of LLL fluctuation (positive/negative) but there
was no correlation between daily LLLV and uGH levels. The
former might be purely due to chance as both indices vary
considerably from day to day. A conclusive evaluation of this
relationship as well as detection of any rhythms requires a
much longer and, therefore, a more demanding study with about
90 pairs of data-points per subject.
Renal handling of GH which can be assessed by measuring
urinary proteins such as beta-2 microglobulin was not
assessed in this study. It is unlikely that our group of
subjects would have had any significant abnormalities of
renal function but day-to-day variation of function might
explain some of the variation in uGH excretion. The study of
other markers such as urinary IGFI could also shed more light
on the observed LLL changes. This study has shown that there
is considerable day-to-day variability in LLL as well as
overnight uGH excretion and the magnitude of uGH excretion
does not correspond to the magnitude of LLL fluctuation. uGH
values should be interpreted with considerable caution and
always in the context of clinical data.
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A M 10.5 1.5
—
B M 11.2 1.9 In same class as D
C M 8.3 1.3 Brother of D
D F 11 1.5 Sister of C
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Fig.3.6. Scattergram of the mean LLLV^ of the 4 subjects




Fig 3.7 Scattergram & mean uGh values of the 4
subjects (A,B,C,D). Error Bars denote 95%CI.
*-p<0.05, **-p<0.005. On the left, uGH excretion
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Fig.3.8 The temporal relationship between LLLV^(solid line)
and uGH values(broken line). LLLV^ error bars denote TE(mm)
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Section 4 Pattern of Growth in Healthy Children
A. Introduction
In the area of growth patterns there are four different
hypotheses under debate. Firstly, there is the model of
saltation and stasis, which is pulsatile growth on a
background of variable durations of stasis (Lampl et al,
1992, Lampl et al, 1995) . Secondly, a model of smooth
continuous growth that proceeds by approximately equal daily
increments has been proposed (Preece & Baines, 1978). The
third model proposes that growth occurs periodically by
constant amplitude increments after equal stasis durations
(Klein et al, 1994, Heinrichs et al, 1995). The final model
hypothesises that growth occurs in a mathematically chaotic
pattern (Wales & Gibson, 1994). Studying the pattern of
short-term growth in healthy children would allow better
interpretation of patterns encountered in disease states and
following potentially growth promoting or suppressive effect
of drugs. As attention is now being paid to short bursts of
hGH treatment in some cases (Kelnar & Tanaka, 1994) , time-
intensive studies might help to direct such treatment to
appropriate phases of growth or stasis.
B. Subjects & Methods
Between August 1993 and June 1994, 30 healthy pre-pubertal
children aged 4.2-10yrs (M:F,12:14) had lower leg
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measurements by one observer at the RHSCE. 26 children were
measured at the same time of the day, on a weekly basis for
12 weeks (Group A) . 4 children were also measured daily
(except weekends) for a period of 4 weeks (Group B). LLL and
weight was measured as described in Chapter Three, Section 2
(B) .
C. Statistical Analysis
LLL changes were expressed as LLL velocity (LLLv) which
represent the relative amount of change that can be detected
between consecutive measurements. In Group A, the changes
were expressed over weekly intervals and in Group B changes
were expressed over daily intervals. Some Group A
measurements were performed at 2-weekly intervals. In Group
B data analysed for assessing change consisted only of
measurements performed on consecutive days. Precision of
knemometric measurements was expressed as TE. Normally
distributed data was described by mean and 95% Confidence
Interval (95%CI) whereas skewed data was described by median
value and 5th and 95th Percentile values (P5,P95). Patterns
of growth were assessed by polynomial regression analysis as
well as frequency distribution of growth velocities.
D. Results
All the children studied remained well over the duration of
the study. The median age of the children was 8.7 (range,
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4.2-10) . Number of measurements performed in Group A was
223; the mean LLLV was 0.39mm/wk (95%CI,0.26-0.52). Number
of measurements performed in Group B was 57; the mean LLLV
was 0.5mm/day ( 95%CI,-0.13-0.20) . The median TE was similar
in both groups at 0.15mm (P10-0.06,P90-0.35). In both groups
LLLV had a normal distribution around a mean value
(Fig.3.9).
There was considerable variation between subjects in the
pattern of growth observed with clear periods of slow and
fast growth (Fig.3.10) as well as times when "negative
growth" or shrinkage was evident. In Group B, who had daily
LLL measurements, the pattern of growth was similar to that
in Group A (Fig.3.11 & Fig.3.12).
To check for any seasonal variation the LLLV of all the
children were grouped according to the month of measurement
(Fig.3.13). Although there was substantial variation, none
of the differences were significant. When the LLLV for the
months September to May were grouped into 3-monthly
"seasons" (autumn,winter,spring) there was still no
statistically significant difference between the groups
although the median LLLV was lower in winter at 0.5mm/wk
(P5,P95,-0.6,1.4) compared to 0.6mm/wk (P5,P95,-1.4,1.9) and




It was clear from this study that the pattern of growth is
highly variable in healthy children. The children in Grp A
did not follow the same pattern of variability. Daily
measurements in a small group of children for a 4 week
period did not make the patterns any clearer or provide any
uniformity. It was, however, interesting to note that the
cumulative LLLV values for the respective groups were
normally distributed around a mean; the mean LLLV was
comparable to that cited in previous studies (Valk et al,
1983) .
The wide variability in the pattern of LLL changes in the
process of linear growth emphasises it's non-uniformity.
Some of the patterns could be classified as saltatory and
others as continuous but there was no consistency and a
large number could not be classified into either. Evaluation
of the chaos model of growth (Wales & Gibson, 1994) would
have required a greater number of consecutive measurements
in the same individual. Patterns of growth are strongly
dependent on the method of analysis as recently suggested by
Johnson et al (1996) who found that data collection
frequency, measurement error and total study duration all
determine the frequency distribution of growth velocities.
The debate regarding the pattern of growth is based on
studies which have been performed not only in children of
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different ages but also in different species. Evaluation of
growth patterns can only occur when these factors have been
standardised.
There was no clear evidence of seasonal variation amongst
this group of subjects. However, the slight reduction in
median LLLV in the winter is in accordance with previous
studies investigating seasonal variation in growth (Gelander
et al, 1994) .
It was, however, clear from this study that non-uniformity
is the rule in the normal growth process and predicting
periods of stasis and growth in a healthy child is not
possible. It also makes it more likely that any changes
which are observed to occur in a uniform fashion in a group
of children could be attributed to coincident external
factors such as disease states or drugs.
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Fig.3.9. Frequency Distribution of LLLV in Group A(top
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Fig 3.10 Pattern of LLL growth in 18 subjects
(A-R). Horizontal Axis-Weeks of Study;Vertical
Axis-LLL(mm); Error Bar-Technical Error of
measurement.
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Fig 3.10 Pattern of LLL growth in 18 subjects
(A-R). Horizontal Axis-Weeks of Study;Vertical
Axis-LLL(mm); Error Bar-Technical Error of
measurement.
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Fig.3.11 Pattern of LLL growth in subjects in
Group B. Horizontal axis-week of study;
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Fig.3.12 Growth Curve of best fit for subjects in




Fig.3.13 Median LLLV with 95th percentile values in Group
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Fig.3.14 Frequency distribution of LLLV according
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CHAPTER FOUR
STUDIES OF SHORT-TERM GROWTH IN CHILDREN
CYTOTOXIC CHEMOTHERAPY
114
This chapter will first present a study performed to
investigate the changes in Height, Weight and Sitting
Height in a group of children receiving cytotoxic
chemotherapy as per the present Medical Research
Council(UK) protocol for treatment of Acute Lymphoblastic
Leukaemia(UKALLXI)(Section 1); Section 2 presents the
changes in LLL in a sub-group over the whole period of
chemotherapy. As it is possible that some of the effects
on short-term growth are due to the anti-mitotic effects
of chemotherapy; this section will also investigate
whether there is a relationship between lower leg growth
and the neutrophil count. The final section will present a
study looking at changes in markers of bone and collagen
turnover and growth hormone secretion in relation to each
other as well as to LLL changes.
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Section 1. Anthropometric study of children during
intensive chemotherapy for acute
lymphoblastic leukaemia
A. Introduction
The effects of cranial irradiation on growth in children
requiring treatment for ALL have been extensively studied
and are well documented (Wallace & Shalet, 1992) . In
UKALLXI, CNS-directed therapy is delivered in the form of
repeated intrathecal methotrexate with or without high-dose
intravenous methotrexate (itMtx & ivHDMtx) for the majority
of patients. There is evidence that CT per se has an adverse
effect on growth (Clayton et al, 1988); however, it is still
not clear whether these effects are temporary and whether
recovery from the growth suppressive effects can occur
during the period of CT (Holm et al, 1994, Hokken-Koelega et
al, 1993, Katz et al, 1991, Moell et al, 1988, Wells et al,
1983, Hakami et al, 1980, Sunderman & Pearson, 1969). There
have been no reported studies of the growth profile of
children on UKALLXI. Concern has also been raised about
altered differential skeletal growth (Makipernaa et al,
1990, Davies et al, 1994) and body disproportion, as well as
obesity (Odame et al, 1994) in children following completion
of CT which has included cranial irradiation.
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This study prospectively documents anthropometric changes
which occurred in a group of children treated by a
chemotherapy-only regimen for ALL.
B. Subjects and Methods
31 children (M:F-20:11) were on UKALLXI over the study
period spanning January 1993-December 1995. From this group
2 pubertal boys, 1 boy with Downs Syndrome and 2 girls and 1
boy who received cranial irradiation were excluded. By the
end of the study 16 children had completed the 2-year course
of CT and remained pre-pubertal. Median age at diagnosis was
4.4yrs (range,1.1-14) . Median duration of study was 18
months (r,3-24). The treatment regimen which the 25 children
received is detailed in Table 4.1.
C. Statistical Analysis
Ht and SH were measured monthly (at the beginning of each
month) by one of two observers with a stadiometer. The SH:Ht
ratio was also calculated for each pair of measurements to
assess any changes in body disproportion. SH measurements
are presented in only 16 children; the remainder were either
too young or did not have a baseline SH measurement. Wt was
measured in standardised clothing on the same Avery scales
throughout the period of study. The Body Mass Index BMI was
2 2
calculated as Wt/Ht" (kg/m ) . The data were converted into
SDS and presented as median change in SDS, with 5th and 95th
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percentile values, from a baseline measurement (ASDS,P5 &
P95) . Conversion of data into SDS was performed with
reference to L,M & S values obtained from the Child Growth
Foundation (Freeman et al, 1995, Cole et al, 1995). Changes
from baseline were tested by WSR analysis for significance.
D. Results
Height - Fig. 4.1(a)
Median ASDS-Ht reached a nadir at 6 months after the start
of CT with a value of -0.35(P5,-0.7;P95,-0.1) p = 0.001.
Subsequently ASDS-Ht remained significantly depressed until
the end of the first year after which it returned to
baseline values.
Weight - Fig. 4.1(b)
Median ASDS-Wt rose significantly over the first month by a
median value of 0.15(P5,-0.15;P95,0.5) p=0.03. After that
initial rise over the period of induction, Wt-SDS was not
significantly different from baseline until the second year
of CT. By the end of CT, median ASDS-Wt was just
significantly raised at 0.5(P5,-0.3;P95,1.0) p=0.04.
Body Mass Index - Fig.4.1(c)
Median ASDS-BMI increased at induction to 0.5(P5,-0.25;P95,
1.64) p=0.002. Median ASDS-BMI was also elevated later in
the 10th month of CT at 0.75(P5,-0.39;P95,1.55) p=0.01.
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Sitting Height - Fig. 4.1(d)
As with Ht, an initial decline is seen in SH followed by a
recovery which seems to be complete by the end of the first
year. Maximum decline was evident at 3 months with a median
ASDS-SH of -0.55(P5,-0.7;P95,-0.2) p=0.02.
Skeletal Disproportion - Fig.4.2
Maximum decline of the SH:Ht ratio was evident at 3 months
with a median ASH:Ht of -0.01(P5,-0.007;P95,0) p=0.009. An
increase from baseline was noticed at 8 months with a median
ASH:Ht of 0.003(P5,0;P95,0.01) p=0.04. By the end of CT
there were no significant changes from baseline.
Effect of Alternative CT Regimens - Fig.4.3
No significant anthropometric differences were observed
between children separated according to the form of CNS-
directed therapy received or whether they received the Third
Intensification block of treatment or not. The number of
children in these subgroups was, however, small for adequate
statistical analysis (Table 4.1).
D. Discussion
A general decline in growth was evident over the first year
of CT but which improved over the second year. The initial
weight gain in the face of reduced growth is most likely due
to corticosteroid therapy during induction and as a
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consequence leads to a significant increase in the BMI. Over
the next few months, body weight is not significantly
different from baseline but height does remain adversely
affected after reaching a nadir at six months after which CT
becomes less intensive. The slow recovery in height with a
satisfactory weight gain could explain the elevation in BMI
in the latter half of the first year. Although the initial
decline in height is consistent with that found in other
studies of children with ALL receiving CT-only regimens, few
studies have shown adequate catch-up growth during the
period of CT (Sunderman & Pearson, 1969, Wells et al, 1983,
Katz et al, 1991) .
Corticosteroids probably play an important role in the early
phase of growth retardation acting, locally on bone growth
(Baron et al, 1992), directly on the growth plate (Brown et
al, 1990), centrally on growth hormone secretion (Giustina
et al, 1990, Marky et al, 1991) as well as by affecting
calcium homeostasis (Gennari, 1994). However, as discussed
in Chapter One, Section 3, almost all the cytotoxic agents
included in the CT protocol can to some extent penetrate the
blood-brain-barrier or have indirect effects on the CNS; Mtx
can have direct effects on bone as well. ivHDMtx has been
associated with lesions in the CNS, the significance of
which is unclear.
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The poor growth after the induction and first
intensification could be due to the CNS-directed therapy.
Whether ivHDMtx has a more profound effect on growth then
repeated itMtx alone was not clear from our data and needs
further investigation. The growth retardation seems to be
reversible, reflecting the results of recent studies
performed by Moell & Garwicz (1995) showing short-term
suppression of growth in rabbits injected with HDMtx.
Our study also revealed an initial transient deceleration in
sitting height which was accompanied by a reduction in the
SH:Ht ratio. This strengthens the hypothesis that the spine
with its multiple growth plates plays a major part in growth
deceleration when exposed directly to cytotoxic CT. Unlike
Davies et al (1994), our group of children did not receive
cranial irradiation and have not reached final height. It
is, however, encouraging to note that there were no
significant differences in body proportion from baseline at
the end of the two year course. It is possible that more
accurate and precise short-term measurements of LLL might
provide a better insight into these growth patterns.
In summary, it seems that UKALLXI CT for ALL affects growth
but there is evidence of recovery before the completion of
treatment. Further study of this cohort of children is
needed to ensure that growth remains unaffected in the long-
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term and an exploration of the underlying physiological
mechanisms of growth decline due to CT is also necessary.
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Table 4.1. The distribution of children receiving the
various forms of chemotherapy within UKALLXI.
Type of CNS-










Total 11 14 25
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Fig.4.1 Median change in (a)Height SDS,(b)Weight
SDS,(c)BMI SDS,(d)Sitting Height SDS,from baseline
in all prepubertal children receiving chemotherapy
only. Boxes denote interquartile ranges *-p<0.05,
**-p<0.005(WSR)compared to baseline. Figures below
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Fig 4.2 Median change in SH:HT ratio from baseline
in all prepubertal children receiving chemotherapy
only. Boxes denote interquartile ranges.*-p<0.05,
**-p<0.005 (WSR)compared to baseline. Figures below

































Fig 4.3 Median change in Ht-SDS from baseline in
children according to type of CNS-directed therapy
(itMTX-continuing intrathecal methotrexate; ivMTX-
intravenous high dose methotrexate)and whether
they received the 3rd intensification(III).




















Section 2 LLL and neutrophil counts in children
on cytotoxic chemotherapy
A. Introduction
This study documents the effect of UKALLXI on short-term
growth during treatment by prospectively measuring LLL in a
sub-group of children from that studied in the previous study
(Chapter Four; Section 1) . After initial presentation, the
neutrophil count in children with ALL reflects the degree of
myelosuppression while on CT and therefore acts as a readily
measurable indirect indicator of the bioeffectiveness of the
CT and a relationship between changes in LLL and neutrophil
counts at the time of febrile neutropenia has previously been
reported by Davies at the meeting of the British Society of
Paediatric Endocrinology in 1994 (Davies, 1995). The fever
confounds the interpretation of the growth deceleration as
the latter is observed in other healthy children who have a
pyrexial illness (Wales & Milner, 1987) . By evaluating
children longitudinally over the CT period including periods
of non-febrile neutropenia this study further enhances our
understanding of the immediate effects of cytotoxic therapy
on growth and investigates the potential for catch-up growth.
B. Subjects & Methods
Between January 1993-December 1995, 31 children (male:
female, 20:11) with a median age of 3.5yrs (range, 1.1-14)
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received treatment for ALL at the Royal Hospital for Sick
Children, Edinburgh. 10 children were too young to co-operate
with knemometry, 3 children received cranial irradiation and
were excluded, 2 children only had incomplete data over the
first 6 months of CT and one child refused to participate in
the study. 15 children with ALL at a median age at diagnosis
of 4.5yrs (range, 2.7-14) were therefore studied. The
children were treated by the UKALLXI treatment protocol as
shown in Figs.2.3-2.5. Each subject was randomised to receive
either intrathecal methotrexate (itMTX) alone or high-dose
intravenous methotrexate with intrathecal methotrexate
(ivMTX) as CNS-directed therapy and to receive or not a third
intensification block at Week 35 of treatment. Table 4.2
shows the outcome of the randomisation of the children in
this study.
Knemometry was performed by the random-zero method by three
trained individuals with a median TE of 0.15mm (5th & 95th
percentiles, 0.06-0.35). In order to coincide the
measurements with the clinic visits, knemometry was performed
in the morning and at approximately the same time at every
visit.
The children were divided into five groups according to when
measurements were performed during their 24-month
chemotherapy protocol. Group A (n=9) had knemometry during
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months 1-6; Group B (n=6), months 1-12; Group C (n=4), months
1-24; Group D(n=9), months 21-27, i.e. 3 months before and 3
months after end of CT (Fig.4.4). Group E (n=ll) consisted of
children who had measurements performed anytime within the
last 18 months of CT.
C. Statistical Analysis
LLLV was derived from either weekly or 2 weekly measurements
of LLL; any data with an interval greater than 2 weeks were
excluded from analysis. LLLV data on each child during any
one month was averaged to provide a median LLLV of the child
for that month of CT. Values are presented as medians with
their 5th and 95th percentile values (P5,P95); within groups
comparison was performed with the Wilcoxon Signed Rank (WSR)
test. Neutrophil counts were transcribed from records held
locally. Evaluation of any relationship between the
neutrophil counts and LLLV was assessed by Spearman's
Correlation Coefficient calculation. Neutrophil counts




A total of 681 measurements of LLL were performed; 67
measurements were omitted from the data analysis as they were
performed at an interval longer than 2 weeks. The median LLLV
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over the first 6 months of CT was 0.20mm/wk (P5,P95:-
0.9,1.0) . In Grp A, there was a significant rise in LLLV
following induction of remission when median LLLV rose from
Omm/wk (P5,P95:-1.6,0.11) during Month 1 to 0.38mm/wk
(P5,P95:-0.04,0.81) during Month 4 (p=0.01) (Fig.4.5). There
was no further significant change in LLLV during CT although
it tended to fall in Month 5 (2nd Intensification) (Fig.4.5).
After CT, median LLLV rose from 0.46mm/wk (P5,P95:
-0.02,0.79) in Month 23 to 0.84mm/ wk (P5,P95: 0.72,1.12)
(p=0.03) in month 25.
LLLV-itMTX vs ivMTX and Third vs No Third Intensification
There were no significant differences in median LLLV observed
during treatment when the subjects were analysed according to
the mode of CNS-directed therapy or according to whether they
received the 3rd Intensification or not (Fig.4.6).
Neutrophil Counts and LLL
The median neutrophil count reached a nadir immediately
following the 1st and 2nd Intensification blocks (i.e.Wk7 and
Wk21) at 0.05xl09/l (range, 0 to 0.13xl09/1)and 0 (range, 0
to 1.5xl09/l), respectively. Although marked changes in
neutrophil counts and LLLV were observed during the first 6
months of treatment we could find no significant relationship
between the two parameters over that period. Over the
following 18 months, which consisted mainly of continuation
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CT but also included the period of Third Intensification
there was a weak but significant positive correlation between
the neutrophil count and LLLV (r2-0.2, p=0.0001) . During this
period median LLLV was 0.2mm/wk (P5,P95: -0.15,0.5) when the
neutrophil count was less than 1.0xl09/l and 0.65mm/wk
(P5,P95: 0.1,1.0) when the count was above 1.0xl09/l (p=0.01)
(Fig.4.7).
E. Discussion
Recent anthropometric studies performed during chemo-therapy
only regimens for children treated for ALL have shown
evidence of growth retardation occurring early during
treatment. However, the point when recovery starts and
whether this recovery is complete seems to be controversial.
The previous study which examined height-SDS as well as Wt-
SDS of a larger cohort of children (Chapter Four; Section 1),
which included the subjects studied here, showed that UKALLXI
had a temporary adverse effect on growth and improvement
occurred within the chemotherapy period.
The study presented in Chapter 3 looking at LLL changes in
healthy children did not reveal any recognisable pattern.
Significant reductions in LLLV were seen over the Induction
and First Intensification periods; although the LLLV was also
low in the Second Intensification period this fall was not
statistically significant. Some of these changes can be
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related to changes in weight and body composition and the
study subjects did gain weight over the period of induction;
besides deceleration actual shrinkage in LLL was also
documented in some of the subjects over this phase and some
of this might be due to direct physical compression of the
compressible parts of the lower leg.
It is likely, however, that part of the deceleration, as well
as shrinkage, is due to the effect of CT. In this study the
period of CNS-directed therapy did not seem to cause any
immediate abnormalities in LLLV and no clear differences in
growth were evident between the itMtx and hdMtx groups. The
short-term suppression of growth in rabbits injected with
hdMtx in the study by Moell & Garwicz (1995) did not fully
recover over the study period. One previous study in children
did not show any significant reduction in lower leg growth
(Tammings et al, 1992).
The degree of catch-up growth documented in this group of
children was impressive and emphasises the transitory nature
of the impairment of normal growth mechanisms. Following the
end of CT, the LLLV reached a supraphysiological level which
would have been consistent with a period of catch-up growth
but only if it had been preceded by a period of impaired
growth(the classical definition of catch-up growth (Williams
et al, 1974) . However, during the second year of chemotherapy
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the LLLV was similar to that recorded for other healthy
children. It is possible that different parts of the skeleton
grow at different rates and that, although the lower leg was
growing at a normal rate during continuation treatment, other
parts such as the spine were not. Non-invasive methods of
measuring vertebral spinal length and studies of bone Sc
collagen turnover as well as GH secretion might shed further
light on the changes seen in this study.
While surgery and some intercurrent illnesses have been shown
to affect growth of the lower leg(Wales & Milner, 1987) no
correlation between LLL changes and any specific parameters
of illness have been described. We excluded possible LLL
changes due to severe intercurrent illness by omitting
knemometry data in children admitted with febrile
neutropenia. The degree of neutropenia during continuation
chemotherapy depends on the doses administered of 6mp and mtx
and outcome of treatment appears more favourable when the
combination is administered to the limits of tolerance as
indicated by the development of neutropenia (Hale &
Lilleyman, 1991, Pearson et al, 1991). While the retardation
of LLLV in association with neutropenia could be due to the
coexistence of a sub-clinical state of catabolism, it is also
possible that 6mp and Mtx have a direct effect on growth. Mtx
has previously been associated with osteopathy (Schwartz and
Leonidas, 1984) and in-vitro studies have shown that 6mp can
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alter hepatic IGF-I metabolism (Morris, 1981). Groot-Loonen
et al (1995) recently suggested that the effect of 6mp and
Mtx on growth may be independent of steroids. Considering the
wide intra and inter-patient variability in drug disposition
and bioavailability of these agents (Teresi et al, 1987,
Lennard & Lilley, 1989), the neutrophil count most accurately
reflects drug activity.
The positive relationship between LLLV and neutrophil count
during the continuation CT period was not observed over the
first 6 months of treatment. Neutrophil counts at
presentation vary between patients and tended to rise (unlike
LLLV) over the induction period before falling after first
intensification. A larger combination of drugs are used
during this period and prolonged courses of drugs such as
high-dose corticosteroids probably affect growth via a number
of different mechanisms.
Although the adverse effect on lower leg growth seems to be
transient, knemometry cannot predict long-term growth and
this cohort of children needs further follow-up to ensure
that growth remains satisfactory. Further in-vitro as well as
in-vivo studies need to be performed to study the effects of
chemotherapeutic agents on longitudinal growth and bone
turnover.
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Table 4.2. The distribution of children receiving the





itMTX 4 2 6
hdMTX 4 4 8
Total 8 6 14
135
Fig 4.4. Description of the five periods of study
and the children studied in those periods.
UKALLXI







Group Number M:F Median Age(Range)
A 9 7:2 5.2 (4.4-14)
B 6 6:0 5.2 (4.4-14)
C 4 4:0 4.8 (4.4-5.2)
D 9 6:3 4.4 (2.7-8.5)
E 12 9:3 4.6 (2.7-14)
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Fig.4.5 Monthly Median LLLV(mm/wk)(95th centiles)





































Fig.4.6 Median LLLV aggregate of each child
(mm/wk) over CT. CNS-directed therapy(CNSDT) and th<
Third Intensification(Intlll) are marked on the
figure. CNSDT was administered as either High Dose
IV Methotrexate(IV) or continuous intrathecal
methotrexate(IT)
Month
1 5 10 15 20 25 30
1 5 10 15 20 25 30
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Fig.4.7 Median LLLV(mm/wk)(95th percentiles) when
neutrophil count was above and below 1x109/L during
continuation chemotherapy.
<1x107 I >1 x 1 07 I
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Section 3. Changes in markers of growth hormone
secretion and bone & collagen turnover
A. Introduction
The studies reported in the preceding two sections reveal a
remarkable pattern of changes in stature as well as LLL in
children on cytotoxic CT and especially during intensive
treatment. While some knemometric changes could be
artefactual and related to changes in weight and soft-tissue
composition, it is probable that they also reflect altered
growth and bone and collagen turnover. Physical growth has
been shown to relate to markers of GH secretion, such as
Insulin Like Growth Factor-1 (IGF1) and IGF Binding Protein-3
(IGFBP3). Although there have been some studies of knemometry
and markers of GH secretion and bone and collagen turnover in
children with asthma, these studies have not extended beyond
eight weeks (Wolthers et al, 1994, Wolthers et al, 1997) . The
aim of this study was to compare knemometry more
comprehensively with these markers of growth. Furthermore,
studying the patterns of changes would provide some insight
into abnormalities in growth pattern seen in children on




Between June 1993 and December 1994, 16 children on UKALLXI
with a median age of 4.5yrs (range,1.1-14) , (M:F, 11:5) , who
were anthropometrically monitored until the end of the second
intensification, had blood and urine samples collected for
the measurement of total Alkaline Phosphatase (tALP), bone
Alkaline Phosphatase (bALP), Carboxy-terminal Propeptide of
Typel Collagen (PICP), Aminoterminal Propeptide of Typelll
Collagen (PIIINP), the Cross-linked Telopeptide of Typel
Collagen (ICTP) as well as urinary Growth Hormone (uGH), IGF1
and IGFBP3. Samples were collected at specific time points in
relation to the CT, as shown in Fig.4.11.
Because of the technique's age restriction, Valk knemometry
was only perfomed in 8 out of the 16 children enrolled above.
Urine collection for uGH assay was performed in only these
subjects whereas blood sampling which coincided with blood
sampling related to the CT regimen was performed in all the
subjects between 10am and midday. Bone and collagen marker
results were available from all the samples collected from
the 16 subjects, whereas GH marker results were only
available in 8 subjects. Details of the subjects are
presented in Table 4.2; in addition to the 14 subjects, 2
subjects who received XRT were studied upto the end of the




tALP activity was measured at 37°C, using p-nitropheny1-
phosphate as substrate in diethanolamine buffer. Its
reference range in children was 250-800U/1 and its interassay
CV were 2.1 and 2.4% at 240 and 506U/1 respectively. ALP
isoenzymes were quantified using a modified wheat germ lectin
affinity electrophoresis method (Crofton, 1992) . The
reference range of the bone isoform (bALP) in children using
this method was 180-700U/1 and its inter-assay CV (in plasma
from children without liver or bone disease) were 2.2, 3.5
and 1.9% at 251, 349 and 435U/1.
PICP and ICTP were both measured by radioimmunoassay (Orion
Diagnostica, Espoo Finland); their reference ranges in
children were 200-460)1/1 and 3 . 5-18 . 0(lg/l respectively. The
inter-assay CV for PICP were 5.8, 4.1, 6.6, and 4.0% at 52,
105, 216 and 435jig/l respectively. The interassay CV for ICTP
were 7.9, 5.7, 6.5, 4.9, 5.2 and 4.1% at 3.3, 6.2, 10.5,
18.8, 2 6.9 and 31.8]lg/l.
PIIINP was also measured by radioimmunoassay (RIA-gnost P-
III-P, Behringewerke AG Diagnostica, Marburg, Germany); its
reference range in children were 0.6-2.1U/ml and it's
interassay CV were 6.9, 6.9, 4.6, 8.6 and 5.1% at 0.89, 0.96,
1.47, 1.57 and 3.98U/ml respectively.
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IGF-I was measured by acid ethanol extraction and
cryoprecipitation of its binding proteins, followed by a
radioimmunoassay using a polyclonal rabbit antiserum raised
against purified human IGF-I. Assays were performed in
duplicate and there was negligible interference by IGFBPs
1,2,3. Half maximal displacement occured at l.l|Ig/l and the
intra and interassay CV at 40% B/B0 including extraction,
were less than 6% and 9%, respectively.
IGFBP-3 was measured by a radioimmunoassay using polyclonal
rabbit antiserum raised against human glycosy-lated IGFBP-3.
Assays were performed in duplicate and there was undetectable
cross-reactivity with IGFBP-1 and 2. Sensitivity of assay was
0.291|lg/l. Interassay CV at 48% and 78% B/B0 was 10.7% and
7.6% respectively. Intra-assay CV at 30%, 40% and 80% B/B0
was 2.3%, 2.4% and 5.9%.
D. Statistical Analysis
Results are presented as median values with their 95th
percentiles. While LLLV and the bone & collagen markers are
presented as absolute values with reference to a normal
range, IGF-I and IGFBP-3 are presented as SD scores (SDS).
The normal ranges as well as the SDS are derived from healthy
children in the laboratories where the assays were performed
(tALP,bALP,IGF1,IGFBP3) or when the assays were performed by
the same method (PICP,P3NP,ICTP) . For uGH, the normal range
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has been defined on the basis of the results of the study of
healthy school-children in Chapter Three; Section3. Inter-
group comparison was performed by the Wilcoxon Signed Rank
test and a relationship between any two variables was
assessed by the Spearman's correlation coefficient test.
E. Results
Markers of Bone and Collagen Turnover
Results for the subgroup who had knemometry are shown
separately (Fig. 4.9) as well as with the rest of the group
(Fig. 4. 10) . It is clear from the figures that the trends
remain in the smaller knemometry sub-group but the changes
are less significant.
bALP and tALP
At presentation both forms of ALP were below the normal range
and tended to rise initially during induction (Wk3) before
reaching a nadir at Wk6 following the first intensification.
Compared to a median tALP of 321U/L (P5,P95:159,466) at Wk3,
median tALP at Wk6 was 201U/L (P5,P95:120,274), p=0.003.
Corresponding values for bALP were Wk3-214U/L
(P5 , P95:89,301) ; Wk6-391U/L (P5,P95:82, 252), p = 0.04 . In
between First and Second Intensification and over the period
of CNS-directed therapy (Wk8-Wkl8), a gradual rise in ALP was
observed. Median tALP at Wkl8 was 315U/L (P5,P95:259,458),
significantly higher than at Wk6 (p=0.003). Median bALP was
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also higher than at Wk6(med bALP,295U/L (P5,P95:203,408)
p=0.02). ALP values then fell to below normal following the
Second Intensification period before rising again. Neither of
the two isoforms ever reached supranormal levels. The
correlation coefficient of tALP and bALP in this group of
children was 0.8,p=0.0001 (Fig. 4. 11) . The ratio of bALP to
total ALP was, however, not constant throughout the six
months (Fig.4.12); at times of intensive CT the bALP isoform
was relatively low and the ratio of bALP to tALP was highest
just before second intensification when LLLV was also high.
PICP
Median PICP at 172|Ig/L (P5 , P95 : 99, 503) was also low at
presentation but, unlike ALP, did not show an intial rise but
fell throughout Induction and First Intensification reaching
a nadir at Wk6 of 101|ig/L ( P5 , P9 5 : 62 , 2 62 ) (Fig.4.9,
Fig.4.10). Median PICP increased more quickly and reached a
peak (supranormal) level at Wkl8 of 699|ig/L ( P5 , P95 : 3 66 , 1226 )
p=0.008. Significant reduction in PICP occurred over the
Second Intensification reaching a second nadir at Wk21 with a
median PICP of 239|!g/L ( P5 , P9 5 : 9 3 , 2 74 , p=0.04) before tending
to rise again.
PIIINP
At a median level of 7.9jIg/L ( P5 , P9 5 : 5 . 9 , 2 8 . 3 ) , PIIINP at
presentation were well within the normal range but like PICP
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showed a gradual decline reaching a nadir at the lower limit
of normality at Wk6 (Median P3NP of 3.8|lg/L ( P5 , P9 5 : 2 . 4 , 6 . 3 )
p=0.003) (Fig.4.9, Fig.4.10). PIIINP reached a peak at Wkl4
(Median PIIINP-11 . 4|Ig/L ( P5 , P9 5 : 6 . 4 , 12 . 3 ) p=0.005); in the
knemometry-only subgroup the peak level was reached later at
Wk20. PIIINP then tended to decline but no significant
changes were seen over the Second Intensification period.
ICTP
Median ICTP at 8 . 4|Ig/L ( P5 , P9 5 : 4 . 3 , 15 . 9 ) was within normal
limits at presentation and a reduction in it's levels was
seen at Wk6 when it fell to 6.4|Ig/L ( P5 , P9 5 : 3 . 9 , 15 . 1) (NS)
(Fig.4.9, Fig.4.10) . Subsequently, there was firstly a
significant increase in ICTP from Wk6 to Wk8 (Median
ICTP, 18 . 4jlg/L (P5,P95: 9.0,33.1) p=0.004) followed by a fall
between Wk8 and Wkl4 (Median ICTP, 14 . 2jlg/L ( P5 , P9 5 : 9 . 6 , 2 5 . 9 )
p=0.04). ICTP fell over the second intensification and showed
a significant rise following the end of that period.
Markers of Growth Hormone Secretion
As the groups are smaller, the results of this study are
presented in toto; the group has not been divided into those
who did and who did not have knemometry (Fig.4.13).
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uGH
uGH was generally higher than that observed in a group of
healthy prepubertal children studied earlier (Fig.4.13).
Median uGH level at presentation (Wkl) was skewed because of
one very high value of 90.3ng/12hrs in Subject E; subsequent
levels in this subject ranged between 3.6 - 8.5ng/12hrs.
Despite excluding this subject uGH excretion continued to
remain above the arbitrary range set in this study. Although
there was a gradual decline of uGH excretion over the first 8
weeks, this change was not significant.
IGF1 and IGFBP3
These two markers of GH secretion/activity showed similar
changes (Fig.4.13). Throughout the study period IGF1-SDS and
IGFBP3-SDS remained within 2SDS of the mean value. Over the
period of induction, systemic levels of IGF1 rose signifi¬
cantly from median IGF1-SDS of -0.9SDS ( P5,P95;-2.7,0.4) at
Wkl to 0.2SDS (P5,P95;-1.9,1.1) at Wk5 (p=0.03). Both median
IGF1 and IGFBP3 reached a peak at Wk20 with values of 0.5SDS
(P5,P95;-0.6,1.6) and 1.9SDS(P5,P95;-0.3,3.1) respectively.
Correlation between LLL and Biochemical Markers (Table 4.3)
Besides a strong relationship between tALP and bALP, a
moderate positive relationship was found between PICP and the
two forms of ALP assayed. There was a weak positive relation¬
ship between most markers of bone turnover as well as IGF-
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related markers of GH secretion. The positive relationship
between IGF-I and IGFBP3 was strong (r2 =0.7, p=0.0001) .
Discussion
This study of the IGF1/GH axis and markers of bone and
collagen turnover over the first six intensive months of
chemotherapy showed that marked changes occurred in these
biochemical markers although the extent of these changes
varied from one to another.
Although the general pattern of changes of the markers
(specially, bone and collagen markers) was similar to that of
the LLL changes, the relationship was not statistically
significant. This is not surprising as changes in the markers
represent all growing bones whereas knemometry reflects
growth of a limited part of the skeleton as well as changes
in soft-tissue composition.
Previous studies have shown that plasma IGF-I and IGFBP3
levels correlate with the diagnosis of GH deficiency and
increase following GH administration (Blum & Ranke, 1990). In
this study of the first 6 months of ALL chemotherapy, IGF-I
and IGFBP3 levels remained within 2SD scores of the mean;
some of the changes seen in IGF-I were significant and the
changes seen in both parameters correlated with some of the
markers of bone formation. The catch-up growth observed in
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the form of an acceleration of LLLV was in the presence of
normal IGF-I and IGFBP3 levels. uGh levels measured over the
first few weeks of chemotherapy were supraphysiologically
high despite normal IGF-I and IGFBP3 levels and a slow LLLV.
These changes could be explained by a transient GH
insensitivity during the intensive chemotherapy period as
suggested by Nivot et al (1994). Both IGF-I and IGFBP3 (to a
lesser extent) can be lowered by malnutrition (Jackson et al,
1995) and the subjects could have been suffering from this at
presentation although this was not apparent from their BMI
which was within the normal range (Chapter Four; Section 1).
Alkylating agents can induce hepatic dysfunction and,
therefore, some of the chemotherapy itself could affect IGF-
I/BP3 synthesis leading to GH insenstivity (Scharf et al,
1996); consistent changes in the ratio of the bone isoform of
ALP to the total ALP which occured over the chemotherapy
period probably reflect changes in hepatic ALP metabolism.
Although total IGF-I levels have been shown to correlate well
with free IGF-I levels (Hasegawa et al, 1996), they probably
do not fully reflect IGF-I activity at the cellular level;
IGFBP3 is thought to modulate the bio-availability of IGF-I
by increasing the biological half-life (Guler et al, 1989)
and by decreasing the transendothelial transport of IGF-I
(Bar et al, 1990). IGFBP3 levels in children with leukaemia
when measured by radioimmunoassay have been previously found
to be in the normal range and significantly higher than that
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measured by western ligand blotting; this was accompanied by
an increase in IGFBP3 protease activity which is most likely
due to the disease process itself (Muller et al, 1994) .
bALP which is produced by the mature osteoblast and reflects
bone mineralisation and PICP, produced by the immature
proliferating osteoblast and which reflects synthesis of
typel collagen (Risteli & Risteli,1993) were both below
normal levels at presentation, demonstrating the growth
suppressive effects of the disease itself. PIIINP which
reflects the synthesis of type III collagen in connective
tissues throughout the body was within the normal range.
ICTP, which is felt to reflect degradation of type I collagen
was within the normal range at presentation and the
combination of the above findings suggest that children with
leukaemia seem to have an imbalance of bone turnover at
presentation which favours bone and collagen degradation.
During the intensive phases of CT within the first 6 months,
i.e. induction, first intensification and second
intensification, all markers of bone formation and
degradation showed reductions which are consistent with the
known suppressive effects of steroids on growth, osteoblast
function and collagen turnover (Chapter One; Section 3(C)).
Unlike the other markers, bALP showed a paradoxical early
increase over the first two weeks of induction followed by
150
subsequent suppression. There was a corresponding increase in
LLLV over this period following which there was a
deceleration. Immediately following the intensive periods of
chemotherapy, bone and collagen markers showed a dramatic
rise with PICP as well as ICTP levels rising above the normal
range. Although ICTP levels rose to a peak at an early stage
following the first 6 weeks of intensive chemotherapy, PICP
and bALP continued to rise and reached a peak at a later
stage. This high level of turnover was mirrored in the
acceleration observed in LLLV following the intensive
chemotherapy. The phase of CNS directed chemotherapy
administered in between First and Second Intensification
periods did not seem to have any apparent detrimental effect
on bone turnover or LLLV. Furthermore, the imbalance in bone
and collagen synthesis during these periods of recovery
favoured bone formation.
Measurement of biochemical markers of bone & collagen
turnover as well as the GH/IGF-I axis has provided some
insight into the growth patterns observed by anthropometry in
children with ALL in Chapter 4; Sections 1 & 2. Knemometry,
as a technique for assessing short-term growth has, to an
extent, been validated by the concurrent changes in the
markers of bone and collagen turnover which can be useful
adjuncts to anthropometric techniques in the assessment of
the risk of growth suppressive effects of drugs. Although
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this study has shown that children receiving cytotoxic
chemotherapy do not show persistent abnormalities of GH/IGF-I
axis and can mount a good recovery of bone and collagen
turnover following intensive chemotherapy, it would be
important to follow this group of children over a longer-term
to ensure adequate growth. Bone mineralisation of adults who
have had cranial irradiation as well as chemotherapy has been
shown to be reduced based on single photon absorptiometry
(Atkinson et al, 1989), dual x-ray absorptiometry (Nussey et
al , 1994) as well as quantitative computed tomography
(Gilsanz et al, 1990) and preliminary studies of children who
have received chemotherapy-only regimens also suggests a
possibilty of reduced mineralisation (Warner et al, 1996);
the present cohort should, therefore, have long-term studies
of bone mineralisation to document their outcome.
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Fig.4.9 Median bALP (U/l) , tALP (U/l) , PICP (|rg/1)
PIINP (jj.g/1) , ICTP(|lg/l) and LLLV(mm/wk) over the
first 6 months of UKALLXI(92) with 95th centile
values in the group of children who had
knemometry.*-p<0.05, * *-p<0.005,WSR. Shaded area
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Fig.4.10 Median bALP (U/1) , tALP (U/1) , PICP (jig/1)
PIINP (jig/1) , ICTP ((lg/1) and LLLV(mm/wk) over the
first 6 months of UKALLXI(92) with 95th centile
values in all the children studied. *-p<0.05,

























































Fig.4.11 Scattergram of bALP(U/l) versus tALP
(U/l).
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Fig.4.12 Median bALP:tALP ratio(95th centiles) over
the first 6 months of UKALLXI(92).*-p<0.05, WSR.
week of chemotherapy
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Fig. 4. 13 Median uGH(ng/mmol creat and ng/12hrs),
IGF-ISDS,IGFBP3SDS & LLLV(mm/wk) over the first six
months of UKALLXI(92)in all children studied.Shaded
area represent approximate reference ranges
15 10 15 20 25
15 10 15 20 25
week
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Table 4.3 Correlation coefficients(r2)and probability
value(p)of markers of bone and collagen turnover,
markers of GH secretion and LLLV
tALP bALP PICP PIIINP ICTP IGF 1 IGFBP3 uGH













































CONCLUSION & FUTURE DIRECTIONS
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Anthropometry is defined as the systematized art of
measuring and taking observations on man, his skeleton, his
brain and other organs by the most reliable means for
scientific purposes (Cameron,1986). This interface between
art and science is a constant theme throughout all fields
of clinical practice and research.
Proficient anthropometry of somatic growth, auxological
anthropometry, is still a form of art but it is the
cornerstone of childhood growth monitoring. It is only
studies based on sound auxology, using techniques such as
stadiometry, that have highlighted adverse long-term
effects of a variety of illnesses and their consequent
treatment. Following such studies, attempts have been made
to study the basis of the harmful effects and subsequently
changes have been introduced to the treatment regimen. The
evolution of the treatment of childhood ALL typifies the
above sequence of events where initial auxology in
survivors not only showed an adverse effect on growth but
also paved the way for research into diverse late effects
of childhood cancer treatment. Besides allowing an
improvement in therapy, such studies have also improved our
understanding of the process of growth.
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As the 5-year survival rate for childhood ALL is now over
70% (Boring et al, 1994) , the major challenge is to
sustain the significant improvement in survival rates while
at the same time minimizing the treatment induced late
effects and, therefore, continued reliance on close
monitoring of growth and other possible late effects
remains necessary. Accurate and reliable detection of
short-term variations in growth rate has long been an
objective of auxological anthropometry. The knemometer,
described just over ten years ago, and with its low
measurement error has been hailed as the method of choice
for such short-term studies. Experience with this technique
is, however, generally limited. At the outset of the
project it was apparent that studies of lower leg length
changes in normal healthy subjects were scarce and most of
the studies which followed subsequently studied knemometry
as a tool for predicting long-term response to GH therapy.
The failure of lower leg length changes to act as a
predictor is no doubt due to the non-linear pattern of
short-term growth. However, my studies show that short-term
growth studies, have the potential to enhance our
understanding of abnormal growth which occurs in a variety
of diverse childhood illnesses and their related treatment.
The studies of short-term growth in healthy children and
adults in this thesis were performed to evaluate the
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technique of knemometry and learn about the pattern of LLL
changes seen in healthy individuals. Knemometry was a very
sensitive method for studying short-term changes in LLL and
it was not particularly difficult to learn. Measurements
were highly reproducible; some of this precision was
artefactual due to intra-observer bias and having
eliminated this in the first study described in this
thesis, the technique still remained highly precise. By
introducing the Random Zero Method into knemometry, new
personnel could be trained more objectively in the
technique and individual measurers could compare the
precison of their technique with minimal observer bias.
The study of LLL in young adults was particularly valuable
in that they (and especially the pregnant subject) acted as
"negative controls" and showed clearly that some of the
changes seen in LLL are unrelated to real growth.
The longitudinal studies in the healthy children have not
solved the debate regarding the pattern of childhood
growth. There is a possibilty that the model of growth
advocated in the literature depends on the method of
mathematical or statistical analysis of the data. Although
it is highly likely that there is a form of biological
control on the process of growth, it might be too
simplistic to expect that this "control" is reflected in a
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distinct pattern of growth when the optimal model of
childhood growth should take environmental as well as
genetic influences into consideration. In the words of
Tanner (1989) "we may write G*E->(GE) where G stands for
genetic and E for environment factors. The product (GE)
develops through time, and the way G and E are related is
shown by a star, not a plus sign nor even a multiplication.
We say that the interaction of genetics and environment is
non-linear, meaning that the effects do not in general
sum". As our knowledge of the biology of growth improves,
it would be appropriate to add that the term "environment"
not only refers to that of the growing child but also to
the growing bones and related tissues. The periods of
acceleration, stasis and deceleration seen in the healthy
group of children occurred without any detectable pattern.
They did not occur in tandem with changes in other children
who were being measured at the time and were not temporally
associated with any obvious external events. This is
important to realise as it implies that reproducible
patterns of lower leg length changes which occur uniformly
at the time of an external stimulus in a group of children
are probably causally related to that stimulus. It is also
important to stress that the terms, LLL "change" or
"fluctuations" rather than growth is preferable as only a
proportion of these changes are due to real changes in
somatic growth.
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Standard anthropometry in this group of children showed a
pattern of growth deceleration which has been seen before
in children during the early phase of intensive treatment
with CT-only regimens. This group of children, however,
showed catch-up growth during the period of CT; this has
not been a universal finding previously. In addition,
significant changes in vertebral growth, body disproportion
and body mass index were seen over the initial phases of
CT; none of these were sustained but emphasis the fact that
CT by itself can significantly affect somatic growth. The
transient alteration in SH:Ht ratio following induction of
remission could have been due to the direct effect of CT on
the numerous vulnerable growth plates in the vertebral
spine.
The studies of short-term growth in children on CT for ALL
have indicated the limitations as well as the advantages of
knemometry over conventional stadiometry. The ability of
the children to show catch-up growth following a period of
significant deceleration as well as real shrinkage(in LLL)
could be observed more closely by knemometry. Whereas,
stadiometry showed that these children reached a nadir in
growth at about six months into therapy before any signs of
improvement, it was clear from knemometry that the lower
leg showed significant catch-up growth very early after
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induction and which was sustained during periods of less
intensive CT over the first six months of treatment. The
delay in the recovery of height could be explained by a
delay in the recovery of the rest of the axial skeleton or
the imprecision of the conventional forms of measurement.
The postive relationship between changes in LLL and
neutrophil counts (which acted as a marker of cytotoxicity
during the period of continuation CT) was interesting and
suggested that the physical changes seen on measurement
were perhaps related to a direct effect of cytotoxic,
myelosuppressive CT on leg growth.
The increase in weight which was related to high dose
steroids during intensive therapy could have contributed to
lower leg length deceleration and shrinkage and the final
study reported in this thesis was performed in order to
investigate as well as relate the changes seen in bone and
collagen turnover and GH secretion. Over this period
changes in markers of bone and collagen turnover were
related to the periods of intensive CT and showed some
temporal association with the changes in LLL. These changes
were not always statistically significant, partly due to
the small sample size but probably also due to the fact
that the markers reflected the general process overall
rather than just the lower leg. The changes in the bone and
collagen markers did suggest some imbalance in turnover
1 6 6
favouring resorption over the induction period and
formation over the period of catch-up growth following
induction. These findings of changes in bone turnover
further support the notion that the LLL changes seen over
these phases of CT relate to real changes in bone growth.
The study of markers of GH secretion suggested a
possibility of partial GH resistance at presentation and
over the first few weeks of CT but this needs to be
validated further. The most remarkable finding was the
presence of marked catch-up growth with no accompanying
increase in the markers of GH secretion supporting the
hypothesis that part of catch-up growth might be GH
independent (Boersma & Wit,1996).
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Future Directions
Knemometry is a useful tool for assessment of short-term
growth provided its limitations are clearly understood. As
new forms of growth promoting, as well as potentially
growth suppressive therapy are introduced, knemometry
could play an important role in the evaluation of any
immediate effect that therapy might have on growth. As
knemometry cannot predict long-term growth, it is
important that subjects involved in studies of short-term
growth are followed up over longer periods. The advantage
of knemometry over biochemical markers of bone turnover in
studying growth is it is non-invasive and with
modifications to the device it is possible to make the
knemometer more portable as well as practicable for
younger age groups. As methods of assessing short-term
growth improve, it might become possible to perform
studies of short-term growth on a larger sample of healthy
children over a longer period to look more conclusively at
the physiology of normal as well as catch-up growth.
Biochemical markers are a useful adjunct in the assessment
of short-term growth; future research in this field should
concentrate in developing new forms of markers which could
be assayed in urine or saliva and therefore become more
easily accessible; at the present time only degradation
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fragments of type I collagen can be measured in the urine.
Besides providing information on somatic growth, bone and
collagen markers provide an insight into mechanisms of
altered bone turnover.
The auxological studies of children on cytotoxic
chemotherapy for ALL in this thesis show that growth is
certainly affected in the short-term; whether there is any
long-lasting effect on growth will only be answered by a
longer study of this cohort as well as results from
studies of other groups of children (for example, those
treated for solid tumours with or outwith the CNS) on the
same and differing chemotherapy regimens. The
abnormalities in bone turnover seen in these children
during treatment raise concern about whether bone
turnover, density and structure are normal in these
children in the long-term and this again will be answered
as this group as well as other comparable groups are
studied in the future. As these changes in bone turnover
coincided with changes in lower leg length, knemometry
could be employed as an indicator of short-term effects on
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Short-Term Changes in Urinary
Growth Hormone Excretion and
Lower Leg Length in Healthy
Children
Abstract
To investigate any association between changes in lower leg length (LLL) and
urinary growth hormone (uGH) excretion, 4 prepubertal children supplied
daily 12-hour overnight urine samples and had daily knemometry performed
for 4 weeks. The mean daily and weekly LLL velocity (LLLV) of the group was
0.08 mm/day (95% CI 0.01-0.18) and 0.52 mm/week (range 0.38-0.78),
respectively. The mean uGH excretion was 8.9 ng/1 (CI 3.7-13.3), and the
mean intrasubject coefficient of variation of uGH was 55>% (range 32-93).
The tallest subject who also had the highest LLLV excreted the least amount of
uGH (mean 3.7 ng/1, CI 2.9-4.5). No temporal relationship was evident
between daily uGH excretion and LLL changes. There was no evidence of any
association between amount ofuGH excreted and LLLV. There remains some
doubt on the usefulness of uGH measurement as the sole predictor of normal
GH production.
Introduction
The process of human growth can be studied in detail
using the knemometer which can non-invasively measure
the lower leg length (LLL) very accurately and precisely
[ 1 ]. In children short-term growth of the lower leg is felt to
progress in a saltatory fashion, and there is evidence to
suggest that the periods of increased growth rates occur in
distinct phases [2],
Knemometry has also revealed an intradaily rhythm in
LLL variability where the length is maximum in the
morning and falls over the first half of the day, reaching a
plateau subsequently [1], This variability has been shown
to relate to the duration ofmaintaining the erect posture,
and the reduction of LLL is thought to be due to weight
bearing on the compressible components of the lower leg
[3]. The growth hormone (GH) secretion, which is maxi¬
mal during the night, could be another factor contributing
to this intradaily rhythm. This is supported by the finding
that serum markers of osteoblastic activity such as osteo¬
calcin and carboxyterminal propeptide of type I procol¬
lagen display a circadian variation in serum concentra¬
tion dependent on the GH secretion [4],
Timed overnight collection of urine for measuring uri¬
nary GH (uGH) provides a non-invasive integrated mea¬
sure of GH secretion [5-7] and may be used as a more
accurate predictor of normality than GH provocation
tests [8], uGH measurements also have a role in studying
the physiology of growth, and it has recently been shown
that the nightly uGH excretion can also vary in a pulsatile
fashion [9],
The aim of this study was to investigate whether there
is any relationship between changes in LLL as evidenced
by knemometry and GH secretion as assessed by over¬
night uGH excretion.
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Subjects and Methods Results
Over a period of 4 weeks in June 1994, measurements were per¬
formed at the Royal Hospital for Sick Children, Edinburgh, on every
weekday in a group of4 healthy children from a neighbouring school.
The LLL was measured with the Valk childhood knemometer as
described before [1], but with a simple modification (random zero
method) designed to reduce operator bias [10, 11], Measurements
were performed by one measurer (S.F.A.) who had been performing
knemometry for a period of 10 months before the onset of this
study.
The subjects were instructed to refrain from any vigorous physi¬
cal activity for 2 h before the measurements were performed and
were permitted to miss any planned physical exercise at school. Care¬
ful record of their bedtime, rising time, and general well-being was
kept. The subjects were given an option to carry on for a further 4
weeks.
Urine for uGH assay was collected as a 12-hour overnight sample.
0.1 % bovine serum albumin was added to the sample at the end of
the collection by the subjects. 1 % thiomersal was added to the sample
by the investigators at midday prior to freezing at -20%. Samples
were analyzed in subject batches at the end of the study with the
Novo Nordisk Novoclone amplified enzyme immunoassay (be-
tween-batch coefficient of variation <12% from 9 to 28 ng/1).
The study was approved by the local ethical committee, and
informed consent was given by all subjects and/or their parents.
Statistics
The daily LLL velocity (LLLVd) was derived from the change in
length from the previous day ofmeasurement and expressed as milli¬
metres per day. LLLV was also derived for the overall study period
from the LLL at baseline and at the end of the study and expressed as
LLLVW in millimetres per week. The precision of knemometric mea¬
surements was expressed as the technical error (TE) and represented
1 SD from the mean of three repeated estimates of LLL. The uGH
levels were expressed as total uGH excreted (uGH<) over 12 h (ng/
12 h) as well as the concentration ofuGH (uGHc) excreted (ng/1). The
relationship between uGH excreted and LLLVd was assessed by cal¬
culating the correlation coefficient, and the Wilcoxon signed-rank
test was used to compare the groups.
Details of the 4 subjects who were all prepubertal are
shown in table 1. The children remained generally well
during the study period, and their bedtime and rising time
in the morning did not vary by more than 1 h. All 4 chil¬
dren declined the offer to continue for a further 4 weeks,
and the primary deterrent was the restriction of physical
activity.
Knemometry was performed on every weekday (20
occasions in each child). The mean TE of the measure¬
ments was 0.18 mm (95% CI 0.16-0.22). Overnight sam¬
ples for uGH assay were collected on 18 occasions by sub¬
ject A and on 17 occasions by subjects B, C, and D.
As a group, the children had a median LLLVW of
0.52 mm/week (range 0.38-0.78) and a median LLLVd of
0.08 mm/day (range 0.01-0.18). Subject B who was the
tallest of the 4 subjects (table 1) had the highest mean
LLLVW as well as LLLVd, but this was not significantly
different from the rest of the group (table 2). The mean
uGHc for the group was 8.9 ng/1 (range 3.9-13.3), and the
mean uGH1 was 1.8 ng (range 1.1-2.4). The uGH excre-
Table 1. Description of subjects
Subject Sex Age Height Comments
years SDS
A male 10.5 1.5
B male 11.2 1.9 in same class as D
C male 8.3 1.3 brother ofD
D female 11.0 1.5 sister ofC
Table 2. Details of LLL changes and
uGH excretion in the 4 subjects Subject








































Fig. 1. Temporal relationship between LLLVd (solid line, mm/
day, left-hand axis) and uGH values (broken line, ng/1, right-hand
axis). LLLVd error bars denote TE (mm).
tion varied widely between as well as within the subjects
(table 2). It was interesting to note that subject B had the
lowest uGH excretion, and his excretion pattern was the
most consistent as suggested by the small confidence lim¬
its.
Although the pattern of variation of uGH excretion
between the subjects was no different when excretion was
expressed as concentration or absolute amount ofuGH, the
differences tended to be more significant when the former
method was employed (table 2). The mean day-to-day coef¬
ficient of variation of uGHc for the whole group was 55%
(range 32-93) and 56% (range 38-89) for uGH1.
Figure 1 shows the temporal relationship between
uGH' and LLLVd. Although there was no significant cor¬
relation between the two variables over the whole dura¬
tion of the study, close examination of the patterns does
shown a temporal relationship at times in subjects A, C,
and D. The mean 12-hour uGHc amounted to 1.5 ng(95%
CI 1.2-1.8) when the LLLVd was negative and to 1.9 ng
(95% CI 1.4-2.4) when the LLLVd was positive (NS).
Discussion
Although significant LLL changes were evident from
day to day in all 4 subjects, no discernible pattern of
change was evident over the 4 weeks. As the leg incorpo¬
rates soft tissue as well as bone, the changes seen in LLLVd
are most likely to represent a combination of changes, of
which some, such as hydration, are transient and some,
such as epiphyseal growth, are permanent. It is for this
reason some researchers have advocated the use of the
term 'fluctuations' rather than 'velocity' to describe the
changes in LLL when assessed over a short period [12].
Our study reinforces the view that healthy children can
excrete a highly variable amount ofuGH from day to day.
This variability was also evident in the study performed
by Thalange et al. [9], but, interestingly, these authors
only rarely encountered a value below their cutoff value
for differentiating normal children from those with GH
deficiency [personal commun.]. Previous studies at our
centre using the Novoclone uGH assay have shown that
timed overnight uGHc reflected nocturnal plasma GH
profiles [13]. These studies have also provided a cutoff
value of around 9 ng/1 [personal commun.] with a small
degree of overlap as encountered in previous studies [5-
8], It is, therefore, interesting to see that subject B who
was growing the fastest had consistently low levels of uGH
excretion and was constantly below our present cutoff val¬
ue for 'normality', subjects A and D also had a substantial
number of uGH values below 9 ng/1. Expression of uGH
data as concentration or as absolute mass did not alter the
coefficient of variation of repeated samples in our group
of subjects. Expression as mass did, however, reduce the
degree of intersubject variability.
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Serial values of uGH can be highly variable, and
although this may be due to true biological variability in
GH secretion or bioavailability controlled by proteins
such as the insulin-like growth factor binding proteins
[14], the variability can also be artefactual due to altera¬
tions in renal clearance of GH [15] or inconsistencies in
handling the urine sample. All the subjects and their par¬
ents were instructed on the collection method and had
instruction sheets with the collection kits. Following the
uGH assays, the participants were again contacted to
check their technique which was recalled correctly. The
urinary creatinine concentration was not measured; al¬
though there was some variation of body height amongst
the subjects, and although subject B with the lowest uGH
levels was the tallest, all the children were prepubertal.
With the limited size of the data it was evident that at
times there was a temporal relationship between uGH
excretion and nature of LLL fluctuation. However, there
was no correlation between daily LLLV and uGH levels.
The former might be purely due to chance, as both indices
vary considerably from day to day [16]. Conclusive evalu¬
ation of this relationship as well as detection of any
rhythms requires a more demanding study with about 90
pairs of data points per subject.
We did not control for renal tubular handling of GH
which can be assessed by measuring urinary proteins such
as (L-microglobulin [17], It is unlikely that our group of
subjects would have had any significant abnormalities of
glomerular or tubular function, but the day-to-day varia¬
tion of function might explain some of the variation in
uGH excretion. The study of markers of bone turnover
and perhaps other indicators of a sustained GH secretion,
such as urinary insulin-like growth factor I [18], could
shed more light on the short-term changes observed
through knemometry.
In conclusion, there is considerable day-to-day vari¬
ability in LLL as well as overnight uGH excretion. The
magnitude of uGH excretion does not correspond to the
magnitude of LLL change. uGH values should always be
interpreted in the context with clinical data. The evalua¬
tion of a temporal relationship between uGH excretion
and LLL changes requires a study at a much larger scale.
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Summary. As the knemometer is increasingly being used to study changes in lower leg
length in conditions associated with weight changes it is important to clearly delineate the
relationship between these two variables. Lower leg length and weight were measured in 26
children and nine adults including one pregnant woman. There was a weak but positive
relationship between lower leg length and weight fluctuation in children. Daily fluctuations
in weight as well as lower leg length were higher in women than men; median lower leg
length fluctuation: women, 016 mm (P5-0, P95-0-7); men, 01mm (P5-0, P95-0-48)
p ~ 0 02, Wilcoxon signed-rank test. Median weight fluctuation: women 015 kg (P5-0,
P95-0-54); men, 01 kg (P5-0, P95-0-5) p = 0-94 (Wilcoxon signed-rank test). Sustained
weight gain in pregnancy led to a reduction in lower leg length followed by an increase
which was coincident with the appearance of dependent oedema. Lower leg length changes
are likely to be positively related to changes in weight when the latter are only modest in
magnitude. However, greater sustained increases in weight are likely to have an opposite
effect on lower leg length due to direct compression of the lower leg. Due consideration of
weight is essential in longitudinal studies of lower leg length changes, especially in conditions
which are associated with significant changes in weight.
1. Introduction
With its high level of accuracy and precision, knemometry has revealed significant
intra- and inter-daily changes in lower leg length in children and adults (Valk,
Langhout-Chabloz, Smals, Kloppenberg, Cassorla and Schutte 1983, Ahmed, Wardaugh,
Duff, Wallace and Kelnar 1995(a)). As the knemometer measures the complete lower
leg, it is possible that these changes may represent alterations in the composition of
subcutaneous tissue, as well as changes in bone and cartilage turnover. Previous
studies have shown anecdotal evidence of an inverse as well as a direct relationship
between lower leg length (LLL) and Weight (Wt) (Hermanussen, Geiger-Benoit,
Burmeister and Sippel 1989, Seidel, Schaefer, Walther and Scharer 1991).
The knemometer is increasingly being used to study short-term changes in LLL
in conditions associated with substantial weight changes (Wales and Milner 1988,
Ahmed, Crofton, Wade, Wallace and Kelnar 1995b) and in this study we have
attempted to delineate the relationship of Wt to LLL by documenting these changes
in a group of healthy children and adults.
2. Method
Between August 1993 and April 1994, 26 prepubertal children (Group A) aged
4-2-10 years (M:F, 12:14) and nine healthy adults aged 29-39 years (M:F, 5:4) had
LLL and Wt measurements. Individual children were measured at the same time of
the day, on a weekly basis for 12 weeks. In seven adults (Group B) knemometry was
performed twice daily, about 8 hours apart for 6 weeks; in the remaining two
(Group C) who were both women, measurements were performed once, 3 days a
0301-4460/96 SI200 © 1996 Taylor & Francis Ltd.
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week, for a period of 8 months. During the study one of the Group C subjects became
pregnant.
Knemometry was performed by an observer-independent method, as previously
described (Ahmed, Wallace and Kelnar 1995c). Subjects in Group A and B were
measured by one observer (S.F.A.) whereas those in Group C were measured by
three observers (S.F.A., B.W., J.D.). Weight was recorded with standardized clothing
on the same Avery scales with an accuracy of 0-05 kg and a standard deviation of
0-05 kg from the mean for three repeated measurements. Standardization for
ingestion, micturition and defaecation were not instituted, in order to facilitate the
enlistment of subjects into the study.
3. Mathematical and statistical analysis
LLL and Wt changes were expressed as fluctuations (LLLf and Wtf) which
represent the amount of absolute change (as opposed to relative change) that can
be detected between consecutive measurements. In Group A the changes were
expressed over weekly intervals and in Groups B and C the changes were expressed
over daily intervals. Some Group A measurements were performed at 2-weekly
intervals. In Groups B and C, data analysed for assessing change consisted only of
measurements performed on consecutive days. Precision of knemometric measure¬
ments was expressed as technical error (TE) and represented 1 SD from the mean of
three estimates of LLL. Normally distributed data were described by 95% confidence
interval (95% CI) whereas skewed data were described by 5th and 95th percentile
values (P5, P95). Spearman's correlation coefficient was used to assess any association
between variables. Inter-group differences were assessed by the Wilcoxon signed-rank
(WSR) test.
4. Results
4.1. Measurements and technical error
The number of measurements performed in Group A was 241; 110 pairs of
measurements were performed in Group B and 123 measurements in Group C. The
median TE was 013 mm (P5-0, P95-0-58).
4.2. LLL and Wt changes in Group A—children
Mean LLLf was 0-83 mm/week (95% CI, 0-74-0-91) and mean Wtf was 0-26 kg/week
(95% CI, 0-23-0-29). In six out of the 26 children there was a direct relationship
between Wt and LLL values (data not shown); none of the children had an inverse
relationship. Cumulative data for the whole of Group A also showed a weak but
highly significant positive relationship (r2 = 0-12, p = 0-0001).
4.3. LLL and Wt changes in Group B—adults
Significant intra-daily variation was seen in only two individuals; both these
individuals were female subjects. For longitudinal fluctuation analysis, the mean of
each day's measurements in every individual was used. Median LLLf was higher in
women at 0-16 mm/day (P5-0, P95-0-7) as compared to 0-1 mm/day (P5-0, P95-0-48)
in men (p = 0 02). This was also true for median Wtf, which was 0-15 kg/day (P5-0,
P95-0-54) as compared to 01 kg/day (P5-0, P95-0-5) in men (p = 0 04).
4.4. LLL and Wt changes in Group C—Pregnancy data
Figure 1 displays the changes in LLL and Wt seen in the two subjects in this
group. The interval with no measurements enables comparison between pre-
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Figure 1. Changes in lower leg length (mm) and body weight (kg) from baseline seen in the pregnant
(top panel) and the non-pregnant (bottom panel) subject in Group C. The Roman numerals denote
the trimester.
confinement and peri-confinement data. As evident in Group B individuals, there
was no significant relationship between day-to-day variation in Wt and LLL in either
individual. However, over the duration of the pregnancy LLL reduced while Wt
increased until a point was reached (beginning of third trimester, in this case) when
LLL started to increase; this increase coincided with the appearance of leg oedema
associated with the pregnancy.
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Zusammenfassung. Da das Knemometer zunehmend haufig benutzt wird, um Veranderungen in der
unteren Beinlange in Situationen zu analysieren, die mit Gewichtsveranderungen assoziiert sind, ist es
sicherlich von groBer Bedeutung, die Beziehung zwischen diesen beiden Variablen zu schildern. Die untere
Beinlange und das Gewicht wurden an 26 Kindern und neun Erwachsenen, darunter eine schwangere
Frau, gemessen. Bei Kindern lieB sich ein schwacher aber positiver Zusammenhang zwischen der unteren
Beinlange und Gewichtsveranderungen beobachten. Tiigliche Fluktuationen im Gewicht und in der
unteren Beinlange waren bei Frauen deutlicher ausgepragt als bei Mannern; die medianen Fluktuationen
in der unteren Beinlange betrugen: 016 mm (P5-0, P95-0-7) bei Frauen, 01 mm (P5-0, P95-0-48) bei
Mannern, p = 0 02 im Wilcoxon signed-rank Test. Die medianen Fluktuationen im Gewicht betrugen:
0-15 kg (P5-0, P95-0-54) bei Frauen und 01kg (P5-0, P95-0-5) bei Mannern, p = 0-04 (Wilcoxon
signed-rank Test). Eine gleichmaBige Gewichtszunahme wahrend der Schwangerschaft fiihrte zu einer
Abnahme der unteren Beinlange, gefolgt von einer Zunahme, die mit dem Auftreten von Odemen
koinzidierte. Veranderungen in der unteren Beinlange sind wahrscheinlich positiv mit Gewichtsverander¬
ungen assoziiert, wenn letztere nur von moderater GroBenordnung sind. GroBere gleichmaBige Gewichts-
zunahmen haben jedoch vermutlich wegen einer direkten Kompression des unteren Beins einen ent-
gegengesetzten Effekt auf die untere Beinlange. Eine gebiihrende Betrachtung des Gewichts in Langs-
schnittstudien zur Veranderung der unteren Beinlange ist wichtig, insbesondere in Situationen, die mit
signifikanten Gewichtsveranderungen verbunden sind.
Resume. Etant donne que le knemometre est de plus en plus utilise pour etudier les changements de
longueur de la jambe dans des conditions associees avec les changements du poids, il est important de
circonscrire clairement la relation existant entre cex deux variables. La longueur de la jambe et le poids
ont ete mesures chez 26 enfants et 9 adultes dont une femme enceinte. II y avait une association faible
mais significative entre la longueur de la jambe et la fluctuation du poids chez les enfants. Les fluctuations
quotidiennes en poids aussi bien qu'en longueur de la jambe, etaient plus elevees chez les femmes que chez
les hommes; fluctuation mediane de la longueur de la jambe: femmes 016 mm (P5-0, P95-0-7); hommes
0-1 mm (P5-0, P95-0-48), p = 002 (Wilcoxon signed-rank test); fluctuation mediane du poids: femmes
015 kg (P5-0, P95-0-54); hommes 01 kg (P5-0, P95-0-5) p = 0-04 (Wilcoxon signed-rank test). Des gains
de poids soutenus au cours de la grossesse conduisant a une reduction de la longueur de la jambe, suivie
d'un accroissement coincidant avec l'apparition d'un oedeme associe. Les changements de la longueur de
la jambe paraissent etre positivement associes aux changements en poids lorsque ceux-ci sont de magnitude
moderee. Cependant, de grands accroissements prolonges de poids sont susceptibles de produire une effet
oppose sur la longueur de la jambe, par suite de la compression directe de la jambe. Une prise en
consideration du poids est essentielle dans les etudes longitudinales des changements de la longueur de
la jambe, en particulier dans les conditions qui sont associees a des changements significatifs du poids.
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Summary. Knemometry is an accurate and non-invasive method of quantifying lower leg
length changes. It reveals multiple fluctuations in leg length velocity over a short period of
measurement, and on the basis of this it has been proposed that short-term growth is
saltatory rather than a continuous phenomenon. The technical error (TE) of the technique
which is generally employed, and which is subject to observer bias, ranges from 0-09 to
0-16mm. This study was undertaken to compare the original method (OM) to a modified
technique which involved measuring from a baseline value of which the operator was not
aware; this technique is referred to as the random zero method (RM). Over a period of 10
months, 58 subjects were measured on 413 occasions. Overall, median TE in the RM group
at 0-15 mm (P5-0, P95-0-65) was higher than the median TE in the OM group at 0-11 mm
(P5-0, P95-0-37). However, the median TE over the last 3 months of 0-15mm (P5-0-05,
P95-0-87) was lower than the TE in the preceding 4 months of 0-20mm (P5-0, P95-0-55)
(WSR,p = 0-04) pointing towards the presence of an operator learning curve. The random
zero method is a simple modification of the original method. It reduces observer bias but
leads to a higher TE, which could explain some of the fluctuations seen between frequent
knemometric measurements. Some knowledge of the length of the training period is
important in the design of new studies involving knemometry; our data suggest that there
should be a learning period of about 4 months if knemometry is performed as often as
quoted above.
1. Introduction
Since the original description by Valk, knemometry has proven to be a very
accurate and non-invasive technique of lower leg measurement (Valk, Langhout-
Chabloz, Smals, Kloppenberg, Cassorla and Schutte 1983). Over a period of a few
weeks it provides growth data which are non-linear, and the consensus among most
investigators is that it is an inadequate tool for predicting long-term growth (Wales
and Gibson 1994). Its main use seems to lie in assessing the effect of therapeutic
interventions, such as steroid therapy, on short-term growth (Wolthers and Pedersen
1992) and, indirectly, studying the physiology of growth.
The method of knemometry in children as described by the original investigators is
now universally accepted (Valk et al. 1983). The technique is easy to acquire, and
although some investigators have suggested that there should be a learning period
(Hermanussen, Geiger-Benoit, Burmeister and Sippel 1988), there are no data
available regarding how long it takes to become proficient. Using the Volk
knemometer, which has an accuracy of 0-1 mm, the technical error (the mean
standard deviation in a series of n independent measurements) (TE) has ranged
between 0-09mm and 0-16mm in previous studies (Hermanussen 1988). As no
modifications of the original method have been described, it is likely that the measurer
in previous studies is not blind to the previous estimations in the set from which each
measurement is derived.
Methods which employ 'blind' lower leg length estimations have been developed
for the neonatal knemometer where the estimations are printed at some distance from
0301-4460/95 $10-00 © 1995 Taylor & Francis Ltd.
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the measurer (Gibson, Pearse and Wales 1993). The TE has been reported to be higher
at 0-3-0-5 mm, and a learning curve was also found using this method.
In this study we describe a simple method which further refines and validates the
technique of knemometry in children. We also investigated further the learning period
for the technique; information which is important for prospective users.
2. Patients and methods
Over the period between August 1993 and May 1994, 50 children aged 4-2-12-8
years, and eight healthy adults, had knemometry performed at the Royal Hospital for
Sick Children in Edinburgh. The children consisted of 26 healthy volunteers from a
neighbouring primary school, 18 children on cytotoxic chemotherapy and six children
with cystic fibrosis. Individual children were measured at the same time of the day
(within an hour's time interval from the first measurement), on a weekly basis, for
periods ranging from 1 to 10 months, depending on the group. The adults were
measured in the last 2 months of the study. Measurements were performed at either
1-weekly or 2-weekly intervals.
Each measurement was derived from a set of four 'estimations'; the most deviant
of the four estimations was eliminated and the mean of the rest was calculated to
provide 'measurement' (Wales and Milner 1987). Measurements were performed
using two methods by a measurer (S.F.A.) who had been instructed by trained
individuals.
The original method (OM) was performed as described previously (Hermanussen
1988). Briefly, the patient sits on a moveable and adjustable chair, the position of
which is customized for each volunteer. The feet rest on a template of the feet drawn
at the first visit and placed on a reference stool. A measuring platform connected to a
Sony digiruler, when lowered onto the surface of the knee, measures the distance
between the two reference points. The distance is displayed on the knemometer's
digital analogue scale. Other controls present on the digiruler include a 'reset' button
which is used for zeroing the device, and a 'preset' button which is for calibrating the
digiruler.
The random zero method (RM) differed from OM in that the baseline reading on
the preset meter was altered by the measurer before each estimation when the
measuring platform was resting at zero. The preset meter was covered with a piece of
paper when the alteration was made, so that the measurer was not aware of the
baseline reading until the end of the estimation. Each estimation was recorded as a set
of two readings, and deduction of the baseline from the actual digital read-out
provided the estimation.
The study was approved by the local ethical committee and informed consent was
given by all subjects and/or their parents.
3. Statistical analysis
The technical error (TE) for each measurement was derived from the standard
deviation of the set of three estimations which make up each measurement as
described in 'Methods'. The TE and coefficient of variation (CV) for each
measurement were calculated and grouped with that of other measurements
performed in the same month. The overall average TE and CV of the two groups (OM
and RM) were presented as median values with their respective 5th and 95th percentile
values (P5 and P95). The Wilcoxon signed-ranked test (WSR) test was used as a non-
parametric test to compare differences between groups.
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4. Results
A total of 413 measurements were performed over the 10-month period; the RM
group consisted of 314 measurements and the OM group consisted of 99. The monthly
breakdown of these measurements is detailed in table 1.
Table 1. Distribution of measurements according to method (random zero vs. original) and month
of study. Figures in parentheses denote the number of measurements performed in adults.












Mean lower leg length velocity in the children was 0-39mm/week (95%-Cl
0-26-0-53). Median TE in the RM and OM group was 0-15 mm (P5-0, P95-0-65) and
0-11 mm (P5-0, P95-0-37), respectively. Median CV in the RM group was 0-06%
(P5-0, P95-0-21), not significantly different from 0-06% (P5-0, P95-0-16) which was
the CV in the OM group.
Adults were measured in the last 2 months of the study period by the random zero
method only. Median TF was 0-36mm (P5-0, P95-0-7) in April and 0-12mm (P5-0,
P95-0-58) in May.
TE and CV reduced in both groups over the period of study (table 2). To analyse
any trend the values for the September and October subgroups in the RM group were
excluded from evaluation as they consisted of relatively small samples, as was the
November subgroup of the OM group. The TE reduced over the first 4 months when
RM was used on a substantial number of occasions (table 2).
Table 2. Median monthly technical error (TE) and coefficient of variation (CV) of measurements
performed by the original method (OM) and the random zero method (RM); 5th and 95th percentile
values in parentheses.
TE-RM TE-OM CV-RM CV-OM
August 0-15 (0-03-0-55) 0-04 (0-0-27)
September 0-13 (0-06-0-2) 0-12 (0-03-0-31) 0-06 (0-02-0-09) 0-07 (0-0-15)
October 0-11 (0-01-0-47) 0-1 (0-04-0-28) 0-04 (0-0-06) 0-04 (0-01-0-14)
November . 0-17 (0-08-1-05) 0-17 (0-0-30) 0-10 (0-02-0-4) 0-10 (0-0-10)
December 0-20 (0-08-0-36) 0-10 (0-02-0-22)
January 0-20 (0-05-0-4) 0-10 (0-02-0-2)
February 0-16 (0-05-1-15) 0-08 (0-02-0-40)
March 0-13 (0-05-1-0) 0-06 (0-02-0-31)
April 0-14 (0-0-58) 0-06 (0-0-18)
May 0-11 (0-0-59) 0-04 (0-0-13)
Differences of TE and CV between consecutive periods of measurement did not
reach significance because of the wide distribution of the values (figure 1). However,












Figure 1. Scattergram of individual TE values of the random zero method (A) and the original
method (B) plotted in chronological fashion.
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grouping together the TE values for the first 4 months (November, December,
January, February) revealed a median value of 0-2mm (P5-0-05, P95-0-87) which
was significantly higher than the TE for the following 3 months at 0-15mm (P5-0,
P05-0-55) (/? = 0*04, WSR).
5. Discussion
The physiology of short-term changes in human growth is still poorly understood.
Although instruments such as the knemometer might shed light on changes not very
far from the cellular level, their limitations, as well as their advantages, must be
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thoroughly assessed. Knemometry, as performed traditionally, is subject to intra-
observer bias which arises as the measurer is aware of the previous estimation in the
series. A reported TE of 0-09mm (Hermanussen 1988) is comparable to more precise
techniques such as kyniklometry (Hermanussen, Bugiel, Aronson and Moell 1992) in
which reproducible estimations are more probably due to better localization of
reference points of measurement.
The RM technique in this study eliminates the observer bias very simply. It can be
performed without any structural modification to the original knemometer, and the
measuring process takes no longer than OM. However, there is one extra step:
deducting the baseline reading from the initial estimation to provide the real
estimation.
Another advantage of RM is that it provides a better guide to the length of the
training period alluded to in previous studies (Hermanussen et al. 1988). We saw a
trend towards lower TE in the RM as well as the OM groups, but this was significant
only for the TE values in the former group. This trend might have become statistically
significant by the high outlying values at the beginning of the study, but the fact that
there were more TE values near zero by the end of the study supports the suggestion of
a real learning curve (figure 1). The lower TE values in the last 2 months were not due
to the introduction of adults into the study, as the TE for that specific subgroup was
slightly higher than the overall value for that month. The low TE values for the first 2
months in the RM group were unrepresentaive as the sample size was small and the
RM measurements were also being performed with extra care, as it was a newly
introduced method. Subjectively, RM took much longer initially than the latter
months.
On the basis of our results we would recommend a period of 3-4 months for
learning, if the knemometer is used as frequently as described above. By using RM
operators can also evaluate their own technique, looking for an improvement and
subsequent plateauing of the TE. To improve the measurement process further, it
would be helpful for the operator if the knemometer could be electronically adapted
so that the series of estimates could be stored, the most deviant estimate omitted and a
TE calculated instantly. If the latter is above an arbitrary limit, then there is scope to
immediately repeat the measurements.
To summarize, we have described a new but simple random zero method of
performing knemometry which reduces observer bias on the part of the measurer but
which does have a higher TE than reported before. This will clearly have implications
on interpreting patterns of short-term growth with multiple fluctuations which might
well be an artifact of measurement rather than a real phenomenon. The method
allows independent evaluation of operator proficiency. This knowledge of the length
of the training period would help new investigators who are designing studies
involving knemometry.
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Zusammenfassung. Knemometrie ist eine exakte und nicht invasive Methode zur Quantifizierung von
Veranderungen in der unteren Beinlange. Sie lafit multiple Fluktuationen in der Wachstumsgeschwindig-
keit der Beinlange tiber kurze Meflintervalle erkennen. Auf dieser Basis wurde vermutet, daB Kurzzeit-
wachstum nicht kontinuierlich verlauft, sondern saltatorisch, d.h. in Spriingen. Der technische Fehler
(TE) dieser Technik, der generell verwendet wird und der Gegenstand des Untersucherbias ist, variiert von
0-09 bis 0- 16mm. Diese Studie dient dazu, die Originalmethode (OM) mit einer modifizierten Technik zu
vergleichen, die darauf basiert, daB von einem Basiswert gemessen wird, der dem Untersucher nicht
bekannt ist. Diese Technik wird als Random Zero Methode (Methode mit einem zufalligen Nullwert, RM)
bezeichnet. Uber einen Zeitraum von 10 Monaten erfolgten an 58 Individuen 413 Messungen. Insgesamt
war der mediane TE in der RM-Gruppe mit 0- 15mm (P5-0, P95-0-65) groBer als der mediane TE in
der OM-Gruppe mit 0-11 mm (P5 -0, P95 -0-37). Der uber die letzten 3 Monate gemittelte TE: 0-15 mm
(P5 -0-05, P95 -0-87) war jedoch geringer als der in den vorhergehenden 4 Monaten: 0-20mm (P5 -0,
P95-0-55) (WSR, /t = 0-04), was fur die Prasenz eines Lerneffekts beim Untersucher spricht. Die RM-
Methode stellt eine einfache Modifikation der Originalmethode dar. Sie reduziert den Untersucherbias,
fiihrt jedoch zu einem hoheren TE was einige Fluktuationen erklaren konnte, die bei haufiger Anwendung
knemometrischer Messungen beobachtet werden konnen. Kenntnisse uber die Lange der Trainingsphase
sind fur das Design neuer knemometrischer Studien von Bedeutung. Die vorliegenden Daten sprechen
dafur, dafi die Lange der Trainingsphase etwa 4 Monate betragen sollte, wenn die Knemometrie so oft,
wie hier erwahnt, durchgefiihrt werden soil.
Resume. La knemometrie est une methode rigoureuse et non invasive de quantification des
modifications de la jambe. Elle a revele de multiples fluctuations dans la velocite de croissance de la jambe
sur une courte periode et cela a conduit a comprendre la croissance au cours de petites periodes comme un
phenomene saltatoire plutot que continu. L'erreur technique (ET) produite par le biais inter-observateur
de la methode de mesure generalement employee est de 0-09 a 0- 16mm. Cette etude a ete entreprise dans
le but de comparer la methode originale (MO) a une technique modifiee: 'methode zero aleatoire' (MA)
qui implique des mesures a partir d'une valeur de base dont l'operateur n'est past informe. 58 sujets ont
ete mesures a 413 reprises sur une periode de 10 mois. L'ET mediane de 0- 15mm (P5-0, P95-0-65)
dans le groupe MA est plus elevee que l'ET mediane du groupe MO a 011mm (P5-0, P95-0-37).
Cependant, l'ET mediane des trois derniers mois, de 0-15 mm (P5 - 0-05, P95 - 0-87) est plus basse que
TET des quatre mois precedents, de 0-20mm (P5 - 0, P95 - 0-55) (WSR, p = 0-04), evoquant la presence
d'une courbe d'apprentissage de Toperateur. La methode zero aleatoire est une simple modification de la
methode originale. Elle reduit le biais du a Tobservateur, mais conduit a une ET plus elevee, ce qui
pourrait expliquer quelques unes des fluctuations constatees entre mesures knemometriques frequentes.
La connaissance de la duree de la periode d'entrainement est importante dans l'organisation de nouvelles
etudes de knemometrie. Nos donnees suggerent qu'elle devrait etre d'environ 4 mois, si la knemometrie
est faite aussi frequemment que decrit ci-dessus.
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Three studies to evaluate procollagen type I C-terminal propeptide, type I col¬
lagen cross-linked telopeptide and bone alkaline phosphatase (BALP) in the
assessment of bone turnover and growth in children are presented. (1) In 50
short normal children treated with placebo or growth hormone, ABALP after
3 months of treatment was highly correlated with height velocity response
after 1 year (r = 0.67, p < 0.0001). (2) In 12 children with acute lymphoblastic
leukaemia, marked changes in collagen peptides, BALP, and lower leg length
velocity were seen during the first 6 months of chemotherapy. Suppression
occurred during induction and the two intensification phases, with catch-up
during the intervening phase (paired t-tests, p < 0.001). (3) Fourteen babies
(birthweight < 1,500 g) treated with high-dose dexamethasone for broncho¬
pulmonary dysplasia were compared with 25 non-steroid-treated babies
< 1.500 g. Both collagen peptides decreased rapidly and dramatically (mean
decreases 41-68%) after dexamethasone was started, accompanied by weight
loss and lower leg shrinkage and followed by recovery during steroid wean¬
ing.
Introduction
Height velocity is central to growth assessment in chil¬
dren but is operator-dependent, insensitive, and impre¬
cise over short time periods [1], Knemometrv overcomes
these disadvantages and has attracted much interest, but
it ignores spinal growth and may be influenced by the
hydration state of overlying soft tissues. All anthropomet¬
ric techniques require a relatively fit, co-operative child.
Biochemical markers of growth are virtually free from
observer bias, reflect whole-body growth rather than
simply that of the lower leg, may be used over short or
long sampling intervals, and have the bonus of giving
insight into the mechanisms of growth variations.
Linear growth occurs predominantly at the epiphyseal
growth plate of the long bones, and is accompanied by
extensive modelling of bone. Osteoblastic bone formation
involves deposition of type I collagen, followed by miner¬
alization and maturation during which stable crosslinks
between collagen fibrils are formed. Procollagen type I
C-terminal propeptide (PICP) is released into the circula¬
tion by proliferating osteoblasts during collagen biosyn¬
thesis [2], The crosslinked telopeptide of type I collagen
(ICTP) is released into the circulation by collagen break¬
down during bone modelling [2]. Bone alkaline phosphate
(BALP) is found in the hypertrophic chondrocytes of the
epiphyseal growth plate, in the matrix vesicles associated
with bone mineralization and in mature osteoblasts [3, 4].
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We have recently reported a close quantitative relation¬
ship between serial measurements of BALP and height
velocity in short normal children undergoing growth hor¬
mone treatment [5].
We present here the results of three studies in which we
have evaluated PICP, ICTP, and BALP in the assessment
of growth and bone turnover in children. All studies were
approved by the local ethical committee: informed con¬
sent was obtained from parents and, where appropriate,
children.
Methods
PICP and ICTP were measured by radioimmunoassay (Orion
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Short Normal Children
Fifty short normal children were treated with placebo
(6), human recombinant growth hormone (GH) alone
(32), GH plus oxandralone (8), or GH plus testosterone
(4). Dosages were: GH 15 or 24 IU/m2/week divided into
daily subcutaneous injections; oxandralone 2.5 mg/day
orally; testosterone undecanoate 40 mg orally on alternate
days. All of the treatment groups except placebo showed
an early significant increase in each of the markers after
3 months of treatment and in height velocity after a year:
p < 0.001 for GH alone, p < 0.05 for the smaller treatment
groups (paired t-tests). The increment in BALP after
3 months gave the best correlation with height velocity
after 1 year (r = 0.67, p < 0.0001 compared with r = 0.54,
p < 0.0001 for PICP and r = 0.41, p = 0.02 for ICTP). The
timing of the 3-month sample may have influenced which
markers gave the best prediction, as PICP and ICTP may
respond earlier than BALP to GH treatment. This study
suggested that BALP in particular might provide a tool for
targeting expensive and invasive growth hormone treat¬
ment to those children most likely to respond with a
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Fig. 1 . Bone turnover markers (mean and SE) in 12 patients with
acute lymphoblastic leukaemia during the first 6 months of chemo¬
therapy: (a) PICP and ICTP; (b) BALP. Induction was from week
1-5, first intensification during week 5, continuing chemotherapy
from weeks 6-20 and second intensification during week 20, with
resumption of continuing chemotherapy from week 21. The samples
from weeks 5 and 20 were each taken before intensification: the sam¬
ples from weeks 6 and 21 were each taken after intensification. Refer¬
ence ranges were as follows: PICP 200-550 gg/1: ICTP 3.5-20.0 pg/1:
BALP 180-600 U/l.
Children on Chemotherapy
There is limited evidence that cytotoxic chemotherapy
may have a detrimental effect oh growth [7] but the pre¬
cise timing, extent, and aetiology of any growth deficit are
unknown. As the current national chemotherapy proto¬
cols [UKALL XI (92)] used to treat children with acute
lymphoblastic leukaemia employ more intensive chemo¬
therapy schedules than those previously investigated [7],
it is important to establish the cost of any increased sur¬
vival to the children in terms of growth impairment, the
phases of chemotherapy that contribute most to any
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Fig. 2. Median and interquartile ranges
of (a) PICP, (b) 1CTP, (c) lower leg length
velocity (LLLV), and (d) weight velocity
(WV) in 25 infants of birthweight less than
1,500 g, who never received steroids.
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growth deficit and the underlying mechanisms of these
growth changes. This information may be of value in
planning future management protocols on a rational ba¬
sis. In a prospective longitudinal study of 12 children with
acute lymphoblastic leukaemia, marked and significant
changes in collagen peptides and BALP were seen during
the first 6 months of chemotherapy (fig. 1). At diagnosis,
PICP and BALP were generally below or close to the low¬
er limit of the reference range, suggesting impairment of
bone growth by the disease process itself. During induc¬
tion and first intensification, the collagen markers were
progressively suppressed, whereas BALP showed initial
recovery before subsequent suppression. We postulate
that these changes were largely due to the prednisolone
component of chemotherapy which was given contin¬
uously (40 mg/m2 orally) throughout induction and first
intensification. Glucocorticoids are known to have an
inhibitory effect on collagen synthesis and degradation
and on the cartilage zones of the growth plate [8-10],
After first intensification (when prednisolone was with¬
drawn), a dramatic catch-up was observed in all bone
markers, with the collagen markers reaching supranormal
concentrations (paired t-tests, p < 0.001). During second
intensification, all markers were again suppressed (p <
0.05), followed by a second catch-up (p < 0.05). This study
illustrates the limitations of knemometry, as many chil¬
dren were too young for the technique. However, in those
forwhom lower leg velocity was available, it paralleled the
changes in PICP and BALP.
Preterm Infants
Among babies who develop bronchopulmonary dys¬
plasia (BPD), high-dose steroids are used with increasing
frequency, but no controlled trials have been carried out
to justify such high dosages. Their effect on bone metabo¬
lism and growth in these infants is unknown. Knemome-
try provides one tool for the investigation of short-term
effects of steroids on growth but, like weight, it may also
be influenced by their diuretic effects. Mineral balance
studies are cumbersome, impractical, and indirect mea¬
sures of bone metabolism. There is a need for simple
robust biochemical markers that will provide surrogate
measures for the effects of steroids on bone turnover and
weighing less than 1,500 g at birth, who developed bron-
57
chopulmonary dysplasia and were treated with high-dose
dexamethasone (500 ]j.g/kg/day for 3 days, followed by
gradually decreasing doses for various periods), were
compared with 25 non-steroid-treated babies weighing
less than 1,500 g over the first 15 weeks of life. All preterm
babies had very high plasma concentrations of collagen
markers compared with older children, indicating very
rapid turnover of bone. In non-steroid-treated babies,
PICP, lower leg length velocity (as measured by serial kne-
mometry), and weight velocity all increased to a plateau
over the first few weeks of life while ICTP decreased, indi¬
cating a net increase in bone formation (fig. 2). After dexa¬
methasone was started in the steroid-treated group, both
PICP and ICTP decreased rapidly and dramatically
(mean decreases 41% and 68% respectively), accompa¬
nied by slowing of radial growth, weight loss, and lower
leg shrinkage. Bone markers and anthropometric indices
recovered during steroid "Weaning, followed by marked
catch-up in some cases. There was evidence that both
weight and knemometry were affected by marked fluid
shifts occurring during steroid administration and wean¬
ing. Under these circumstances collagen markers are like¬
ly to provide a more reliable index of growth than anthro¬
pometric measures.
Conclusions
In the first of the studies described here, BALP was
helpful in giving an early prediction of growth response to
GH treatment. In the other two, the markers of bone col¬
lagen turnover were of particular value in assessing acute
changes in bone turnover and growth in response to clini¬
cal interventions.
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Twenty-fourepisodesoster idadministrationi13babies( significant'differencesbetwe n successiveepisodesofdexametha ontr atm nt). bPartialrecoverywasdefinedsthosfexam ih oneu gster idingthich measurementsbegantoincr saft rh vi ge chedth irnad r. cFullrecoverywasdefinedasthosefexam ih oneuri g( rft r)ster idingw i h measurementsregainedthdiav lufoequival ntpostnatalain25babies(birthw g t< 1,500g)whohadneverbe ntreat di hsteroids.
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In order to study the short- to medium-term effects of cytotoxic chemotherapy
(CT) for acute lymphoblastic leukaemia (ALL) on growth in prepubertal chil¬
dren, a prospective study of weight (Wt), height (Ht), sitting height (SH) and
body mass index (BMI) was performed in 31 children receiving intensive CT
for ALL. Two pubertal children, 1 child with Down's syndrome and 3 children
who had cranial irradiation were excluded from the analysis. Monthly mea¬
surements were presented as change in standard deviation scores from base¬
line (ASDS). The median age at diagnosis was 4.4 years (range, 1.1-14). The
median duration of study per subject was 18 months (3-24). The median
ASDS-Ht reached a nadir of-0.35 at 6 months after the start of CT (p = 0.001,
Wilcoxon signed rank test); the median ASDS-SH was -0.55 at 3 months (p =
0.02); the median ASDS-Wt and ASDS-BMI increased at 2 months to 0.15 (p =
0.03) and 0.5 (p = 0.002), respectively. The median ASDS-BMI was also ele¬
vated at 10 months (0.75, p = 0.01) reflecting the relative delay in recovery of
Ht-SDS in comparison to Wt-SDS. The median SH:Ht ratio, a measure of
disproportion, was reduced at 3 months (ASH:Ht ratio, -0.01, p = 0.009). No
significant changes in Ht-SDS. BMI-SDS or SH:Ht from baseline were evident
at the end of the CT. Cytotoxic CT for ALL in childhood has a significant
adverse effect on growth, but there is some evidence for recovery before the
endofCT.
Introduction
The effects of cranial irradiation on growth in children
requiring treatment for acute lymphoblastic leukaemia
(ALL) have been extensively studied and are well docu¬
mented [1], In the present trial of ALL treatment in the
UK (UKALLXI), CNS-directed therapy is delivered in
the form of repeated intrathecal methotrexate (MTX)
with or without high-dose intravenous MTX for the ma¬
jority of patients. There is evidence that chemotherapy
(CT) per se has an adverse effect on growth [2]; however,
it is still not clear whether these effects are temporary and
whether recovery from the growth-suppressive effects can
occur during the period of CT [3-9], There have been no
reported studies of the growth profile of children on
UKALLXI. Recently, some concern has been raised
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Fig. 1. The UKALLXI treatment protocol; the First 6 months includes induction, first (I) and second (II) intensifi¬
cation as well as CNS-directed therapy which can either be in the form of continuing intrathecal (it) MTX or high-
dose intravenous (HD-iv) MTX as well as intrathecal MTX. The second 6 months may include the third intensifica¬
tion (III); the next year consists of continuation chemotherapy also administered between the specific treatment
blocks mentioned above.
about altered differential-skeletal growth [10, 11] and
body disproportion, as well as obesity [12] in children fol¬
lowing completion of CT protocols which have included
cranial irradiation.
This study prospectively documents anthropometric
changes which occurred in a group ofchildren treated by a
CT-onlv regimen for ALL.
Subjects and Methods
31 children (M:F, 20:11) were on UKALLXI over the study peri¬
od spanning January 1993 to December 1995. From this group, 2
pubertal boys, 1 boy with Down's syndrome and 2 girls and 1 boy
who received cranial irradiation were excluded. By the end of the
study, 16 children had completed the 2-vear course of CT and
remained prepubertal. The median age at diagnosis was 4.4 years
(range, 1.1-14). The median duration of study was 18 months (range,
3-24).
A brief description ofUKALLXI and its randomisation steps are
presented in figure 1. Induction CT consists of prednisolone 40 mg/
m2 o.d., weekly vincristine 1.5 mg/m:, asparaginase 6,000 U/m2 (9
doses) and intrathecal MTX (2 doses). First and second intensifica¬
tion periods last for a week and consist of prednisolone 40 mg/m2
o.d., vincristine 1.5 mg/m2 (1 dose), daunorubicin 45 mg/m2 (2
doses), etoposide 100 mg/m: (5 doses), cytarabine 100 mg/m: b.i.d.,
thioguanine 80 mg/m: o.d. and intrathecal MTX (1 dose). High-dose
MTX treatment consists of 3 pulses of intravenous MTX (8 mg/m;)
as well as 3 doses of intrathecal MTX. During the third intensifica¬
tion period which lasts for 8 weeks, children receive dexamethasone
10 mg/m: for 14 days, vincristine 1.5 mg/m2 (4 doses), asparaginase
6,000 U/m2 (9 doses), intrathecal MTX (2 doses), cyclophosphamide
600 mg/m2 (2 doses), cytarabine 75 mg/m2 (16 doses) and thiogua¬
nine 60 mg/m2 o.d. The treatment regimen which the 25 children
received is detailed in table 1.
Height (Ht) and sitting height (SH) were measured monthly (at
the beginning ofeach month) by one of two observers with a stadiom-
Table 1. The distribution of children receiving the various forms
ofCT within UKALLXI
Type of CNS-directed Third No third Total
therapy intensi¬ intensi¬
fication fication
MTX onlv 4 5 9
Intravenous high-dose and
intrathecal MTX 7 9 16
Total 11 14 25
eter. The SH:Ht ratio was also calculated for each pair of measure¬
ments to assess any changes in body disproportion. SH measure¬
ments are presented in only 16 children; the remainder were either
too young or did not have a baseline SH measurement. Weight (Wt)
was measured in standardised clothing on the same Avery scales
throughout the period of study. The body mass index (BMI) was cal¬
culated as Wt/Ht: (kg/m2). The data were converted into standard
deviation scores (SDS) and presented as median change in SDS, with
5th and 95th percentile values, from a baseline measurement (ASDS.
P5 and P95). Conversion of data into SDS was performed with refer¬
ence to L, M and S values obtained from the Child Growth Founda¬
tion [13. 14], Significance of any change from baseline was assessed
by the Wilcoxon signed rank (WSR) test.
Results
Height
Median ASDS-Ht (fig. 2a) reached a nadir at 6 months
after the start of CT with a value ot -0.35 (P5, -0.7; P95,
-0.1; p = 0.001). Subsequently ASDS-Ht remained signifi¬
cantly depressed until the end of the first year afterwhich it
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Fig. 2. Median change in Ht SDS (a), Wt
SDS (b), BMI SDS (c) and SH SDS (d) from
baseline in all prepubertal children receiving
CT only. Boxes denote interquartile ranges.
*
p < 0.05. ** p < 0.005 (WSR) compared to
baseline. Figures below the boxes represent
the number ofmeasurements.
returned to baseline values. These trends were also present
in a small group of 14 cases where Ht measurements were
available from the beginning to the end of CT (fig. 3).
Weight
Median ASDS-Wt (fig. 2b) rose significantly over the
first month by a median value of 0.15 (P5, -0.15; P95,
0.5; p = 0.03). After that initial rise over the period of
induction. Wt-SDS was not significantly different from
baseline until the second year of CT. By the end ot CT,
median ASDS-Wt was just significantly raised at 0.5 (P5.
-0.3; P95, 1.0; p = 0.04).
180 Horm Res 1997:48:178-183 Ahmed/Wallace/Kelnar
1.25t
Fig. 3. Median change in Ht SDS from
baseline in 14 prepubertal children receiving
CT. Boxes denote interquartile ranges. * p <
0.05, ** p < 0.005 (WSR) compared to base¬
line. Figures below the boxes represent the
number ofmeasurements.
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Fig. 4. Median change in SH-Ht ratio
from baseline in all prepubertal children re¬
ceiving CT only. Boxes denote interquartile
ranges. * p < 0.05, ** p < 0.005 (WSR) com¬
pared to baseline. Figures below the boxes
represent the number ofmeasurements.
month of chemotherapy
BodyMass Index
Median ASDS-BMI (fig. 2c) increased at induction to
0.5 (P5, -0.25; P95, 1.64; p = 0.002). Median ASDS-BMI
was also elevated later in the 10th month of CT at 0.75
(P5, -0.39; P95, 1.55; p = 0.01).
Sitting Height
As with Ht, an initial decline is seen in SH (fig. 2d)
followed by a recovery which seems to be complete by the
end of the first year. Maximum decline was evident at
3 months with a median ASDS-SH of -0.55 (P5, -0.7;
P95, -0.2; p = 0.02).
Skeletal Disproportion
Maximum decline of the SH:Ht ratio (fig. 4) was evi¬
dent at 3 months with a median ASH:Ht of -0.01 (P5,
-0.007; P95, 0; p = 0.009). An increase from baseline was
noted at 8 months with a median ASHiHt of 0.003 (P5, 0;
P95, 0.01; p = 0.04). By the end of CT there were no sig¬
nificant changes from baseline.
Effect ofAlternative CTRegimens
No significant anthropometric differences were ob¬
served between children separated according to the form
of CNS-directed therapy received or whether they re¬
ceived the third intensification block of treatment or not.
The number of children in these subgroups was, however,
small for adequate statistical analysis (table 1).
Discussion
The results of our study show a general decline in
growth over the first year of CT but which tends to
improve over the second year. The initial weight gain in
the face of reduced growth is most likely due to corticoste¬
roid therapy during induction and as a consequence leads
to a significant increase in the BMI [15]. Over the next
few months, body weight is not significantly different
from baseline but Ht does remain adversely affected after
reaching a nadir at 6 months after which CT becomes less
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intensive. The slow recovery in Ht with a satisfactory Wt
gain could explain the elevation in BMI in the latter half
of the first year. Although the initial decline in Ht is con¬
sistent with that found in other studies of children with
ALL receiving CT-only regimens [1-10], few studies have
shown adequate catch-up growth during the period of CT
[3,5,7].
Corticosteroids probably play an important role in the
early phase of growth retardation acting locally on bone
growth [16], directly on the growth plate [17] and central¬
ly on growth hormone secretion [18, 19] as well as by
affecting calcium homoeostasis [20]. However, almost all
the cytotoxic agents included in the CT protocol can to
some extent penetrate the blood-brain barrier [21-25] or
have indirect effects on the CNS [26]; MTX can have
direct effects on bone as well [27],
Intravenous high-dose MTX has been associated with
lesions in the CNS [28], the significance of which is
unclear. The poor growth after the induction and first
intensification could be due to the CNS-directed therapy.
Whether intravenous MTX has a more profound effect on
growth than repeated intrathecal MTX alone was not
clear from our data and needs further investigation. The
growth retardation seems to be reversible, reflecting the
results of recent studies showing short-term suppression
of growth in rabbits injected with high-dose MTX [29],
Our study also revealed an initial transient decelera¬
tion in SH which was accompanied by a reduction in the
SH:Ht ratio. This strengthens the hypothesis that the
spine with its multiple growth plates plays a major part in
growth deceleration when exposed directly to cytotoxic
CT [11]. Unlike Davies et al. [11], our group of children
did not receive cranial irradiation and have not reached
final Ht. It is, however, encouraging to note that there
were no significant differences in body proportion from
baseline at the end of the 2-vear course. It is possible that
more accurate and precise short-term measurements of
lower leg length [30] might provide a better insight into
these growth patterns.
In summary, our results show that UKALLXI chemo¬
therapy for ALL in childhood does adversely affect
growth, but there is evidence of recovery occurring before
the completion of treatment. Further study of this cohort
of children is needed to ensure that growth remains unaf¬
fected in the long term and further studies are also
required to explore the underlying physiological mecha¬
nisms of growth decline due to CT. To understand the
effects of the various forms ofCT, further studies compar¬
ing the different regimens within UKALLXI would also
be advantageous.
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